Journal Articles Published In 2022

2775998 TCMBXKKM 2022 1 padagogische-hochschule-bern-institut-vorschulstufe-und-primarstufe 50 date desc 3759 https://www.iedea-sa.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22C6QYX8MN%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyakato%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNyakato%2C%20P.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChrist%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAnderegg%2C%20N.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuhairwe%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJefferys%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20High%20Unreported%20Mortality%20in%20Children%20and%20Youth%20%28%26lt%3B25%20Years%29%20Living%20With%20HIV%20Who%20Were%20Lost%20to%20Care%20From%20Antiretroviral%20Therapy%20Programs%20in%20Southern%20Africa%3A%20Results%20From%20a%20Multicountry%20Tracing%20Study.%20%26lt%3Bi%26gt%3BJ%20Acquir%20Immune%20Defic%20Syndr%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B91%26lt%3B%5C%2Fi%26gt%3B%20%285%29%2C%20S.%20429%26%23x2013%3B433.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003090%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003090%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High%20Unreported%20Mortality%20in%20Children%20and%20Youth%20%28%3C25%20Years%29%20Living%20With%20HIV%20Who%20Were%20Lost%20to%20Care%20From%20Antiretroviral%20Therapy%20Programs%20in%20Southern%20Africa%3A%20Results%20From%20a%20Multicountry%20Tracing%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyakato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Jefferys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22van%20Lettow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20J.%22%2C%22lastName%22%3A%22Phiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20Southern%20Africa%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Antiretroviral%20therapy%20program%20mortality%20maybe%20underestimated%20if%20deceased%20patients%20are%20misclassified%20as%20lost.%20METHODS%3A%20We%20used%20two-stage%20inverse%20probability%20weighting%20to%20account%20for%20probability%20of%20being%3A%20sampled%20for%20tracing%20and%20found%20by%20the%20tracer.%20RESULTS%3A%20Among%20680%20children%20and%20youth%20aged%20%26lt%3B25%20years%20on%20antiretroviral%20therapy%20who%20were%20lost%20and%20traced%20in%20Southern%20Africa%20between%20October%202017%20and%20November%202019%2C%20estimated%20mortality%20was%20high%20at%209.1%25%20%2862%5C%2F680%29.%20After%20adjusting%20for%20measured%20covariates%20and%20within-site%20clustering%2C%20mortality%20remained%20lower%20for%20young%20adults%20aged%2020-24%20years%20compared%20with%20infants%20aged%20%26lt%3B2%20years%20%5Badjusted%20hazard%20ratio%3A%200.40%20%2895%25%20confidence%20interval%3A%200.31%20to%200.51%29%5D.%20CONCLUSIONS%3A%20Our%20study%20confirms%20high%20unreported%20mortality%20in%20children%20and%20youth%20who%20are%20lost%20and%20the%20need%20for%20tracing%20to%20assess%20vital%20status%20among%20those%20who%20are%20lost%20to%20accurately%20report%20on%20program%20mortality.%22%2C%22date%22%3A%22Dec%2015%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003090%22%2C%22ISSN%22%3A%221944-7884%20%28Electronic%29%201525-4135%20%28Print%29%201525-4135%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22LHALPPPF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McCann%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMcCann%2C%20N.%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BStanic%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BPenazzato%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BFlanagan%2C%20C.%20F.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAbrams%2C%20E.%20J.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%26%23x2019%3BIvoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%2812%29%2C%20S.%20e26045.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26045%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20undiagnosed%20HIV%20among%20children%20in%20South%20Africa%2C%20Cote%20d%27Ivoire%20and%20Zimbabwe%3A%20a%20model-based%20analysis%20to%20inform%20paediatric%20HIV%20screening%20programmes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22McCann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Stanic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20F.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Dugdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%22%2C%22lastName%22%3A%22Neilan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20A.%22%2C%22lastName%22%3A%22Freedberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Fassinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Doherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mushavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20I.%22%2C%22lastName%22%3A%22Soeteman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Ciaranello%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20To%20improve%20the%20diagnosis%20and%20survival%20of%20children%20living%20with%20HIV%20%28CLWH%29%2C%20the%20World%20Health%20Organization%20recommends%20testing%20approaches%20beyond%20traditional%20infant%20HIV%20testing%20programmes.%20Information%20about%20undiagnosed%20HIV%20prevalence%20among%20children%20of%20varying%20ages%20in%20the%20general%20population%20is%20needed%20to%20guide%20innovative%20national%5C%2Fsubnational%20case-finding%20and%20testing%20approaches.%20METHODS%3A%20We%20used%20the%20Cost-Effectiveness%20of%20Preventing%20AIDS%20Complications%20%28CEPAC%29-Pediatric%20model%20to%20estimate%20the%20prevalence%20of%20undiagnosed%20HIV%20in%202-%2C%205-%20and%2010-year-old%20children%20in%20South%20Africa%2C%20Cote%20d%26%23039%3BIvoire%20and%20Zimbabwe%20in%202018.%20We%20simulated%20cohorts%20of%20children%20born%20in%202008%20%2810-year-olds%29%2C%202013%20%285-year-olds%29%20and%202016%20%282-year-olds%29.%20Country-%5C%2Fyear-specific%20inputs%20for%20pregnant%5C%2Fbreastfeeding%20women%20included%3A%20HIV%20prevalence%20%284.2-32.3%25%29%2C%20HIV%20incidence%20%280.03-0.24%25%5C%2Fmonth%29%2C%20knowledge%20of%20HIV%20status%20%2827-89%25%29%20and%20antiretroviral%20drug%20coverage%20%2836-95%25%29.%20Paediatric%20inputs%20included%20early%20infant%20testing%20coverage%20%286-95%25%29%20and%20breastfeeding%20duration%20%280-20%20months%29.%20We%20projected%20the%20proportion%20of%20surviving%20CLWH%20in%20whom%20HIV%20remained%20undiagnosed%20and%20the%20undiagnosed%20HIV%20prevalence%20among%20surviving%20children%20of%20each%20age%20in%20the%20general%20population.%20For%20children%20born%20in%202016%2C%20we%20projected%20survival%20and%20diagnosis%20of%20all%20CLWH%20through%202026.%20We%20conducted%20sensitivity%20analyses%20on%20model%20parameters.%20RESULTS%3A%20In%202018%2C%20the%20projected%20proportion%20of%20surviving%20CLWH%20whose%20HIV%20remained%20undiagnosed%20in%20South%20Africa%5C%2FCote%20d%26%23039%3BIvoire%5C%2FZimbabwe%20was%2044.2%25%5C%2F55.8%25%5C%2F52.9%25%20among%202-year-old%20CLWH%3B%2029.0%25%5C%2F37.8%25%5C%2F33.2%25%20among%205-year-old%20CLWH%3B%20and%2018.3%25%5C%2F25.4%25%5C%2F23.1%25%20among%2010-year-old%20CLWH.%20Projected%20general%20population%20undiagnosed%20HIV%20prevalence%20in%20South%20Africa%5C%2FCote%20d%26%23039%3BIvoire%5C%2FZimbabwe%20was%200.44%25%5C%2F0.32%25%5C%2F0.68%25%20among%202-year-olds%3B%200.25%25%5C%2F0.17%25%5C%2F0.41%25%20among%205-year-olds%3B%20and%200.24%25%5C%2F0.14%25%5C%2F0.38%25%20among%2010-year-olds.%20Among%20all%20CLWH%20born%20in%202016%2C%2050-54%25%20were%20projected%20to%20die%20without%20HIV%20diagnosis%20%28and%20subsequently%20without%20treatment%29%20within%2010%20years%20after%20birth%3B%2080-85%25%20of%20these%20deaths%20occurred%20in%20the%20first%202%20years.%20CONCLUSIONS%3A%20Projected%20population-level%20undiagnosed%20HIV%20prevalence%20is%20low%20and%20sharply%20decreases%20after%20age%202%2C%20with%20more%20CLWH%20dying%20than%20being%20diagnosed.%20Despite%20low%20undiagnosed%20prevalence%20in%20the%20general%20population%20of%20older%20children%2C%20we%20project%20that%20a%20large%20proportion%20of%20CLWH%20remain%20undiagnosed%2C%20suggesting%20that%20innovative%20strategies%20targeting%20untested%20children%20of%20all%20ages%20outside%20of%20health%20facility%20settings%20should%20be%20prioritized.%20Programmes%20could%20consider%20routine%20testing%20of%20the%20general%20population%20of%20children%20below%202%20in%20all%20settings%20and%20children%20of%20all%20ages%20in%20high-prevalence%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26045%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A24%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22P6SLCVLG%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChihota%2C%20B.%20V.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMandiriri%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BShamu%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuula%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNyamutowa%2C%20H.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%2812%29%2C%20S.%20e26047.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26047%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20syndrome%20among%20treatment-naive%20people%20living%20with%20and%20without%20HIV%20in%20Zambia%20and%20Zimbabwe%3A%20a%20cross-sectional%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nyamutowa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Taderera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mwamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%22%2C%22lastName%22%3A%22for%20Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Chronic%20viral%20replication%20has%20been%20linked%20to%20an%20increased%20risk%20of%20cardiovascular%20and%20metabolic%20diseases%20in%20people%20living%20with%20HIV%20%28PLWH%29%2C%20but%20few%20studies%20have%20evaluated%20this%20association%20in%20Southern%20Africa.%20We%20explored%20the%20determinants%20of%20metabolic%20syndrome%20%28MetS%29%20among%20treatment-naive%20adults%20living%20with%20and%20without%20HIV%20in%20Southern%20Africa.%20METHODS%3A%20Treatment-naive%20PLWH%20and%20people%20living%20without%20HIV%20%28PLWOH%29%20%26gt%3B%5C%2F%3D30%20years%20were%20consecutively%20enrolled%20from%20primary%20care%20clinics%20in%20Zambia%20and%20Zimbabwe.%20PLWOH%20were%20seronegative%20partners%20or%20persons%20presenting%20for%20HIV%20testing.%20We%20defined%20MetS%20as%20the%20presence%20of%20central%20obesity%20plus%20any%20two%20of%20the%20following%3A%20raised%20blood%20pressure%2C%20impaired%20fasting%20glucose%2C%20reduced%20high-density%20lipoprotein%20cholesterol%20and%20raised%20triglycerides%2C%20as%20defined%20by%20the%20International%20Diabetes%20Federation.%20We%20used%20logistic%20regression%20to%20determine%20factors%20associated%20with%20MetS.%20RESULTS%3A%20Between%20August%202019%20and%20March%202022%2C%20we%20screened%201285%20adults%20and%20enrolled%20420%20%2847%25%29%20PLWH%20and%20481%20%2853%25%29%20PLWOH.%20The%20median%20age%20was%20similar%20between%20PLWH%20and%20PLWOH%20%2840%20vs.%2038%20years%2C%20p%20%26lt%3B%200.24%29.%20In%20PLWH%2C%20the%20median%20CD4%28%2B%29%20count%20was%20228%20cells%5C%2Fmm%283%29%20%28IQR%20108-412%29%20and%20the%20viral%20load%20was%2024%2C114%20copies%5C%2Fml%20%28IQR%20277-214%2C271%29.%20Central%20obesity%20was%20present%20in%20365%5C%2F523%20%2870%25%29%20females%20and%2057%5C%2F378%20males%20%2815%25%29.%20MetS%20was%20diagnosed%20in%20172%5C%2F901%20%2819%25%2C%2095%25%20confidence%20interval%20%5BCI%5D%2017-22%25%29%2C%20and%20prevalence%20was%20higher%20among%20females%20than%20males%20%2827%25%20vs.%209%25%29.%20In%20multivariable%20analyses%2C%20HIV%20status%20was%20not%20associated%20with%20MetS%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.05%2C%2095%25%20CI%200.74-1.51%29.%20Risk%20factors%20for%20MetS%20included%20age%20older%20than%2050%20years%20%28aOR%202.31%2C%2095%25%20CI%201.49-3.59%29%2C%20female%20sex%20%28aOR%203.47%2C%2095%25%20CI%202.15-5.60%29%2C%20highest%20income%20%28aOR%202.19%2C%2095%25%20CI%201.39-3.44%29%20and%20less%20than%20World%20Health%20Organization%20recommended%20weekly%20physical%20activity%20%28aOR%203.35%2C%2095%25%20CI%201.41-7.96%29.%20CONCLUSIONS%3A%20We%20report%20a%20high%20prevalence%20of%20MetS%20and%20central%20obesity%20among%20females%20in%20urban%20Zambia%20and%20Zimbabwe.%20Lifestyle%20factors%20and%20older%20age%20appear%20to%20be%20the%20strongest%20predictors%20of%20MetS%20in%20our%20population%2C%20with%20no%20evident%20difference%20in%20MetS%20prevalence%20between%20treatment-naive%20PLWH%20and%20PLWOH.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26047%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A34%3A26Z%22%7D%7D%2C%7B%22key%22%3A%224QMJKWAF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBrazier%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAjeh%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMaruri%2C%20F.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMusick%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BFreeman%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%2812%29%2C%20S.%20e26036.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22d%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Interruptions%20in%20treatment%20pose%20risks%20for%20people%20with%20HIV%20%28PWH%29%20and%20threaten%20progress%20in%20ending%20the%20HIV%20epidemic%3B%20however%2C%20the%20COVID-19%20pandemic%26%23039%3Bs%20impact%20on%20HIV%20service%20delivery%20across%20diverse%20settings%20is%20not%20broadly%20documented.%20METHODS%3A%20From%20September%202020%20to%20March%202021%2C%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%20surveyed%20238%20HIV%20care%20sites%20across%20seven%20geographic%20regions%20to%20document%20constraints%20in%20HIV%20service%20delivery%20during%20the%20first%20year%20of%20the%20pandemic%20and%20strategies%20for%20ensuring%20care%20continuity%20for%20PWH.%20Descriptive%20statistics%20were%20stratified%20by%20national%20HIV%20prevalence%20%28%26lt%3B1%25%2C%201-4.9%25%20and%20%26gt%3B%5C%2F%3D5%25%29%20and%20country%20income%20levels.%20RESULTS%3A%20Questions%20about%20pandemic-related%20consequences%20for%20HIV%20care%20were%20completed%20by%20225%20%2895%25%29%20sites%20in%2042%20countries%20with%20low%20%28n%20%3D%2082%29%2C%20medium%20%28n%20%3D%2086%29%20and%20high%20%28n%20%3D%2057%29%20HIV%20prevalence%2C%20including%20low-%20%28n%20%3D%2057%29%2C%20lower-middle%20%28n%20%3D%2079%29%2C%20upper-middle%20%28n%20%3D%2039%29%20and%20high-%20%28n%20%3D%2050%29%20income%20countries.%20Most%20sites%20reported%20being%20subject%20to%20pandemic-related%20restrictions%20on%20travel%2C%20service%20provision%20or%20other%20operations%20%2875%25%29%2C%20and%20experiencing%20negative%20impacts%20%2876%25%29%20on%20clinic%20operations%2C%20including%20decreased%20hours%5C%2Fdays%2C%20reduced%20provider%20availability%2C%20clinic%20reconfiguration%20for%20COVID-19%20services%2C%20record-keeping%20interruptions%20and%20suspension%20of%20partner%20support.%20Almost%20all%20sites%20in%20low-prevalence%20and%20high-income%20countries%20reported%20increased%20use%20of%20telemedicine%20%2885%25%20and%20100%25%2C%20respectively%29%2C%20compared%20with%20less%20than%20half%20of%20sites%20in%20high-prevalence%20and%20lower-income%20settings.%20Few%20sites%20in%20high-prevalence%20settings%20%282%25%29%20reported%20suspending%20antiretroviral%20therapy%20%28ART%29%20clinic%20services%2C%20and%20many%20reported%20adopting%20mitigation%20strategies%20to%20support%20adherence%2C%20including%20multi-month%20dispensing%20of%20ART%20%2895%25%29%20and%20designating%20community%20ART%20pick-up%20points%20%2844%25%29.%20While%20few%20sites%20%285%25%29%20reported%20stockouts%20of%20first-line%20ART%20regimens%2C%2010-11%25%20reported%20stockouts%20of%20second-%20and%20third-line%20regimens%2C%20respectively%2C%20primarily%20in%20high-prevalence%20and%20lower-income%20settings.%20Interruptions%20in%20HIV%20viral%20load%20%28VL%29%20testing%20included%20suspension%20of%20testing%20%2822%25%29%2C%20longer%20turnaround%20times%20%2841%25%29%20and%20supply%5C%2Freagent%20stockouts%20%2822%25%29%2C%20but%20did%20not%20differ%20across%20settings.%20CONCLUSIONS%3A%20While%20many%20sites%20in%20high%20HIV%20prevalence%20settings%20and%20lower-income%20countries%20reported%20introducing%20or%20expanding%20measures%20to%20support%20treatment%20adherence%20and%20continuity%20of%20care%2C%20the%20COVID-19%20pandemic%20resulted%20in%20disruptions%20to%20VL%20testing%20and%20ART%20supply%20chains%20that%20may%20negatively%20affect%20the%20quality%20of%20HIV%20care%20in%20these%20settings.%22%2C%22date%22%3A%22Dec%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26036%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A27%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22RS2J6KLL%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Iskandar%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BIskandar%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTaghavi%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BLow%2C%20N.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBramer%2C%20W.%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEgger%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Mathematical%20Models%20for%20Evaluating%20Effectiveness%20and%20Cost-Effectiveness%20of%20Cervical%20Cancer%20Control%20Policies%20in%20Populations%20Including%20Women%20Living%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Scoping%20Review.%20%26lt%3Bi%26gt%3BValue%20Health%20Reg%20Issues%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B32%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%2039%26%23x2013%3B46.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.vhri.2022.07.001%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.vhri.2022.07.001%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mathematical%20Models%20for%20Evaluating%20Effectiveness%20and%20Cost-Effectiveness%20of%20Cervical%20Cancer%20Control%20Policies%20in%20Populations%20Including%20Women%20Living%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Scoping%20Review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Iskandar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20M.%22%2C%22lastName%22%3A%22Bramer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Mathematical%20modeling%20is%20increasingly%20used%20to%20inform%20cervical%20cancer%20control%20policies%2C%20and%20model-based%20evaluations%20of%20such%20policies%20in%20women%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20are%20an%20emerging%20research%20area.%20We%20did%20a%20scoping%20review%20of%20published%20literature%20to%20identify%20research%20gaps%20and%20inform%20future%20work%20in%20this%20field.%20METHODS%3A%20We%20systematically%20searched%20literature%20up%20to%20April%202022%20and%20included%20mathematical%20modeling%20studies%20evaluating%20the%20effectiveness%20or%20cost-effectiveness%20of%20cervical%20cancer%20prevention%20strategies%20in%20populations%20including%20women%20living%20with%20HIV.%20We%20extracted%20information%20on%20prevention%20strategies%20and%20modeling%20approaches.%20RESULTS%3A%20We%20screened%201504%20records%20and%20included%2022%20studies%2C%20almost%20half%20of%20which%20focused%20on%20South%20Africa.%20We%20found%20substantial%20between-study%20heterogeneity%20in%20terms%20of%20strategies%20assessed%20and%20modeling%20approaches%20used.%20Fourteen%20studies%20evaluated%20cervical%20cancer%20screening%20strategies%2C%207%20studies%20assessed%20human%20papillomavirus%20vaccination%20%28with%20or%20without%20screening%29%2C%20and%201%20study%20evaluated%20the%20impact%20of%20HIV%20control%20measures%20on%20cervical%20cancer%20incidence%20and%20mortality.%20Thirteen%20conducted%20cost-effectiveness%20analyses.%20Markov%20cohort%20state-transition%20models%20were%20used%20most%20commonly%20%28n%20%3D%2012%29.%20Most%20studies%20%28n%20%3D%2017%29%20modeled%20the%20effect%20of%20HIV%20by%20creating%20HIV-related%20health%20states.%20Thirteen%20studies%20performed%20model%20calibration%2C%20but%2011%20did%20not%20report%20the%20calibration%20methods%20used.%20Only%201%20study%20stated%20that%20model%20code%20was%20available%20upon%20request.%20CONCLUSIONS%3A%20Few%20model-based%20evaluations%20of%20cervical%20cancer%20control%20strategies%20have%20specifically%20considered%20women%20living%20with%20HIV.%20Improvements%20in%20model%20transparency%2C%20by%20sharing%20information%20and%20making%20model%20code%20publicly%20available%2C%20could%20facilitate%20the%20utility%20of%20these%20evaluations%20for%20other%20high%20disease-burden%20countries%2C%20where%20they%20are%20needed%20for%20assisting%20policy%20makers.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.vhri.2022.07.001%22%2C%22ISSN%22%3A%222212-1102%20%28Electronic%29%202212-1099%20%28Print%29%202212-1099%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22NHY3V5N6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tlali%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTlali%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BScheibe%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRuffieux%2C%20Y.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCornell%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BWettstein%2C%20A.%20E.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Diagnosis%20and%20treatment%20of%20opioid-related%20disorders%20in%20a%20South%20African%20private%20sector%20medical%20insurance%20scheme%3A%20A%20cohort%20study.%20%26lt%3Bi%26gt%3BInt%20J%20Drug%20Policy%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B109%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20103853.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2022.103853%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2022.103853%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20and%20treatment%20of%20opioid-related%20disorders%20in%20a%20South%20African%20private%20sector%20medical%20insurance%20scheme%3A%20A%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Scheibe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20E.%22%2C%22lastName%22%3A%22Wettstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20use%20of%20opioids%20is%20increasing%20globally%2C%20but%20data%20from%20low-%20and%20middle-income%20countries%20on%20opioid-related%20mental%20and%20behavioural%20disorders%20%28hereafter%20referred%20to%20as%20opioid-related%20disorders%29%20are%20scarce.%20This%20study%20examines%20the%20incidence%20of%20opioid-related%20disorders%2C%20opioid%20agonist%20use%2C%20and%20excess%20mortality%20among%20persons%20with%20opioid-related%20disorders%20in%20South%20Africa%26%23039%3Bs%20private%20healthcare%20sector.%20METHODS%3A%20We%20analysed%20longitudinal%20data%20of%20beneficiaries%20%28%26gt%3B%5C%2F%3D%2011%20years%29%20of%20a%20South%20African%20medical%20insurance%20scheme%20using%20reimbursement%20claims%20from%20Jan%201%2C%202011%2C%20to%20Jul%201%2C%202020.%20Beneficiaries%20were%20classified%20as%20having%20an%20opioid-related%20disorder%20if%20they%20received%20an%20opioid%20agonist%20%28buprenorphine%20or%20methadone%29%20or%20an%20ICD-10%20diagnosis%20for%20harmful%20opioid%20use%20%28F11.1%29%2C%20opioid%20dependence%20or%20withdrawal%20%28F11.2-4%29%2C%20or%20an%20unspecified%20or%20other%20opioid-related%20disorder%20%28F11.0%2C%20F11.5-9%29.%20We%20calculated%20adjusted%20hazard%20ratios%20%28aHR%29%20for%20factors%20associated%20with%20opioid-related%20disorders%2C%20estimated%20the%20cumulative%20incidence%20of%20opioid%20agonist%20use%20after%20receiving%20an%20ICD-10%20diagnosis%20for%20opioid%20dependence%20or%20withdrawal%2C%20and%20examined%20excess%20mortality%20among%20beneficiaries%20with%20opioid-related%20disorders.%20RESULTS%3A%20Of%201%2C251%2C458%20beneficiaries%2C%201286%20%280.1%25%29%20had%20opioid-related%20disorders.%20Between%202011%20and%202020%2C%20the%20incidence%20of%20opioid-related%20disorders%20increased%20by%2012%25%20%2895%25%20CI%209%25-15%25%29%20per%20year.%20Men%2C%20young%20adults%20in%20their%20twenties%2C%20and%20beneficiaries%20with%20co-morbid%20mental%20health%20or%20other%20substance%20use%20disorders%20were%20at%20increased%20risk%20of%20opioid-related%20disorders.%20The%20cumulative%20incidence%20of%20opioid%20agonist%20use%20among%20beneficiaries%20who%20received%20an%20ICD-10%20diagnosis%20for%20opioid%20dependence%20or%20withdrawal%20was%2018.0%25%20%2895%25%20CI%2014.0-22.4%29%203%20years%20after%20diagnosis.%20After%20adjusting%20for%20age%2C%20sex%2C%20year%2C%20medical%20insurance%20coverage%2C%20and%20population%20group%2C%20opioid-related%20disorders%20were%20associated%20with%20an%20increased%20risk%20of%20mortality%20%28aHR%202.28%2C%2095%25%20CI%201.84-2.82%29.%20Opioid-related%20disorders%20were%20associated%20with%20a%207.8-year%20shorter%20life%20expectancy.%20CONCLUSIONS%3A%20The%20incidence%20of%20people%20diagnosed%20with%20or%20treated%20for%20an%20opioid-related%20disorder%20in%20the%20private%20sector%20is%20increasing%20rapidly.%20People%20with%20opioid-related%20disorders%20are%20a%20vulnerable%20population%20with%20substantial%20psychiatric%20comorbidity%20who%20often%20die%20prematurely.%20Evidence-based%20management%20of%20opioid-related%20disorders%20is%20urgently%20needed%20to%20improve%20the%20health%20outcomes%20of%20people%20with%20opioid-related%20disorders.%22%2C%22date%22%3A%22Nov%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.drugpo.2022.103853%22%2C%22ISSN%22%3A%221873-4758%20%28Electronic%29%200955-3959%20%28Print%29%200955-3959%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22YFEMMRJZ%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kassanjee%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKassanjee%2C%20Reshma%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20Mary-Ann%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNgwenya%2C%20Olina%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BOsei-Yeboah%2C%20Richard%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJacobs%2C%20Theuns%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20COVID-19%20among%20adults%20living%20with%20HIV%3A%20Correlates%20of%20mortality%20in%20a%20general%20population%20in%20a%20resource-limited%20setting.%20%26lt%3Bi%26gt%3BMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%202022.10.17.22281085.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.10.17.22281085%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.10.17.22281085%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20among%20adults%20living%20with%20HIV%3A%20Correlates%20of%20mortality%20in%20a%20general%20population%20in%20a%20resource-limited%20setting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olina%22%2C%22lastName%22%3A%22Ngwenya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Osei-Yeboah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theuns%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erna%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Venessa%22%2C%22lastName%22%3A%22Timmerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Britz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jantjie%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicki%22%2C%22lastName%22%3A%22Tiffin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesbert%22%2C%22lastName%22%3A%22Zinyakatira%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20While%20a%20large%20proportion%20of%20people%20with%20HIV%20%28PWH%29%20have%20experienced%20SARS-CoV-2%20infections%2C%20there%20is%20uncertainty%20about%20the%20role%20of%20HIV%20disease%20severity%20on%20COVID-19%20outcomes%2C%20especially%20in%20lower%20income%20settings.%20We%20studied%20the%20association%20between%20mortality%20and%20characteristics%20of%20HIV%20severity%20and%20management%2C%20and%20vaccination%2C%20among%20adult%20PWH.%5CnMETHODS%3A%20We%20analysed%20observational%20cohort%20data%20on%20all%20PWH%20aged%20%5Cu226515%20years%20experiencing%20a%20diagnosed%20SARS-CoV-2%20infection%20%28until%20March%202022%29%2C%20who%20accessed%20public%20sector%20healthcare%20in%20the%20Western%20Cape%20province%20of%20South%20Africa.%20Logistic%20regression%20was%20used%20to%20study%20the%20association%20of%20mortality%20with%20CD4%20cell%20count%2C%20viral%20load%2C%20evidence%20of%20ART%2C%20time%20since%20first%20HIV%20evidence%2C%20and%20vaccination%2C%20adjusting%20for%20demographic%20characteristics%2C%20comorbidities%2C%20admission%20pressure%2C%20location%20and%20time%20period.%5CnRESULTS%3A%20Mortality%20occurred%20in%205.7%25%20%2895%25%20CI%3A%205.3%2C6.0%29%20of%2017%20831%20first%20diagnosed%20infections.%20Higher%20mortality%20was%20associated%20with%20lower%20recent%20CD4%2C%20no%20evidence%20of%20ART%20collection%2C%20high%20or%20unknown%20recent%20viral%20load%20%28among%20those%20with%20ART%20evidence%29%2C%20and%20recent%20first%20HIV%20evidence%2C%20differentially%20by%20age.%20Vaccination%20was%20protective.%20The%20burden%20of%20comorbidities%20was%20high%2C%20and%20tuberculosis%2C%20chronic%20kidney%20disease%2C%20diabetes%20and%20hypertension%20were%20associated%20with%20higher%20mortality%2C%20more%20strongly%20in%20younger%20adults.%5CnCONCLUSIONS%3A%20Mortality%20was%20strongly%20associated%20with%20suboptimal%20HIV%20control%2C%20and%20prevalence%20of%20these%20risk%20factors%20increased%20in%20later%20COVID-19%20waves.%20It%20remains%20a%20public%20health%20priority%20to%20ensure%20PWH%20are%20on%20suppressive%20ART%20and%20vaccinated%2C%20and%20manage%20any%20disruptions%20in%20care%20that%20occurred%20during%20the%20pandemic.%20The%20diagnosis%20and%20management%20of%20comorbidities%2C%20including%20for%20tuberculosis%2C%20should%20be%20optimised.%22%2C%22date%22%3A%222022-10-17%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2022.10.17.22281085%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222025-03-17T15%3A39%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22AWBVNXEF%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marti%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMarti%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BZurcher%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEnane%2C%20L.%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDiero%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMarcy%2C%20O.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%2810%29%2C%20S.%20e26018.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26018%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20COVID-19%20pandemic%20on%20TB%20services%20at%20ART%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multi-cohort%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Khusuwan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Reubenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20global%20consortium%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20COVID-19%20stretched%20healthcare%20systems%20to%20their%20limits%2C%20particularly%20in%20settings%20with%20a%20pre-existing%20high%20burden%20of%20infectious%20diseases%2C%20including%20HIV%20and%20tuberculosis%20%28TB%29.%20We%20studied%20the%20impact%20of%20COVID-19%20on%20TB%20services%20at%20antiretroviral%20therapy%20%28ART%29%20clinics%20in%20low-%20and%20middle-income%20countries.%20METHODS%3A%20We%20surveyed%20ART%20clinics%20providing%20TB%20services%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20in%20Africa%20and%20the%20Asia-Pacific%20until%20July%202021%20%28TB%20diagnoses%20until%20the%20end%20of%202021%29.%20We%20collected%20site-level%20data%20using%20standardized%20questionnaires.%20RESULTS%3A%20Of%2046%20participating%20ART%20clinics%2C%2032%20%2870%25%29%20were%20in%20Africa%20and%2014%20%2830%25%29%20in%20the%20Asia-Pacific%3B%2052%25%20provided%20tertiary%20care.%20Most%20clinics%20%2885%25%29%20reported%20disrupted%20routine%20HIV%20care%20services%20during%20the%20pandemic%2C%20both%20in%20Africa%20%2884%25%29%20and%20the%20Asia-Pacific%20%2886%25%29.%20The%20most%20frequently%20reported%20impacts%20were%20on%20staff%20%2852%25%29%20and%20resource%20shortages%20%2837%25%3B%20protective%20clothing%2C%20face%20masks%20and%20disinfectants%29.%20Restrictions%20in%20TB%20health%20services%20were%20observed%20in%2012%20clinics%20%2826%25%29%2C%20mainly%20reduced%20access%20to%20TB%20diagnosis%20and%20postponed%20follow-up%20visits%20%286%5C%2F12%2C%2050%25%20each%29%2C%20and%20restrictions%20in%20TB%20laboratory%20services%20%2822%25%29.%20Restrictions%20of%20TB%20services%20were%20addressed%20by%20dispensing%20TB%20drugs%20for%20longer%20periods%20than%20usual%20%287%5C%2F12%2C%2058%25%29%2C%20providing%20telehealth%20services%20%283%5C%2F12%2C%2025%25%29%20and%20with%20changes%20in%20directly%20observed%20therapy%20%28DOT%29%20%28e.g.%20virtual%20DOT%2C%203%5C%2F12%29.%20The%20number%20of%20TB%20diagnoses%20at%20participating%20clinics%20decreased%20by%2021%25%20in%202020%20compared%20to%202019%3B%20the%20decline%20was%20more%20pronounced%20in%20tertiary%20than%20primary%5C%2Fsecondary%20clinics%20%2824%25%20vs.%2012%25%29%20and%20in%20sites%20from%20the%20Asia-Pacific%20compared%20to%20Africa%20%2846%25%20vs.%2014%25%29.%20In%202021%2C%20TB%20diagnoses%20continued%20to%20decline%20in%20Africa%20%28-8%25%29%20but%20not%20in%20the%20Asia-Pacific%20%28%2B62%25%29%20compared%20to%202020.%20During%20the%20pandemic%2C%20new%20infection%20control%20measures%20were%20introduced%20or%20intensified%20at%20the%20clinics%2C%20including%20wearing%20face%20masks%2C%20hand%20sanitation%20and%20patient%20triage.%20CONCLUSIONS%3A%20The%20COVID-19%20pandemic%20led%20to%20staff%20shortages%2C%20reduced%20access%20to%20TB%20care%20and%20delays%20in%20follow-up%20visits%20for%20people%20with%20TB%20across%20IeDEA%20sites%20in%20Africa%20and%20the%20Asia-Pacific.%20Increased%20efforts%20are%20needed%20to%20restore%20and%20secure%20ongoing%20access%20to%20essential%20TB%20services%20in%20these%20contexts.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26018%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222025-03-11T14%3A46%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22HGA3VZX4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Turdo%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTurdo%2C%20Y.%20Q.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRuffieux%2C%20Y.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBoshomane%2C%20T.%20M.%20G.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMouton%2C%20H.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTaghavi%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cancer%20treatment%20and%20survival%20among%20cervical%20cancer%20patients%20living%20with%20or%20without%20HIV%20in%20South%20Africa.%20%26lt%3Bi%26gt%3BGynecol%20Oncol%20Rep%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B43%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20101069.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gore.2022.101069%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gore.2022.101069%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20treatment%20and%20survival%20among%20cervical%20cancer%20patients%20living%20with%20or%20without%20HIV%20in%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20Q.%22%2C%22lastName%22%3A%22Turdo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20M.%20G.%22%2C%22lastName%22%3A%22Boshomane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Mouton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20compare%20cancer%20treatment%20and%20all-cause%20mortality%20between%20HIV-positive%20and%20HIV-negative%20cervical%20cancer%20patients%20in%20South%20Africa.%20METHODS%3A%20We%20assessed%20cancer%20treatment%20and%20all-cause%20mortality%20in%20HIV-positive%20and%20HIV-negative%20cervical%20cancer%20patients%20who%20received%20cancer%20treatment%20within%20180%20days%20of%20diagnosis%20using%20reimbursement%20claims%20data%20from%20a%20private%20medical%20insurance%20scheme%20in%20South%20Africa%20between%2001%5C%2F2011%20and%2007%5C%2F2020.%20We%20assessed%20treatment%20provision%20using%20logistic%20regression%20and%20factors%20associated%20with%20all-cause%20mortality%20using%20Cox%20regression.%20We%20assigned%20missing%20values%20for%20histology%20and%20ethnicity%20using%20multiple%20imputation.%20RESULTS%3A%20Of%20483%20included%20women%2C%20136%20%2828%20%25%29%20were%20HIV-positive%20at%20cancer%20diagnosis%20%28median%20age%3A%2045.7%20years%29%2C%20and%20347%20%2872%20%25%29%20were%20HIV-negative%20%28median%20age%3A%2054.1%20years%29.%20Among%20285%20patients%20with%20available%20ICD-O-3%20morphology%20claims%20codes%2C%20the%20proportion%20with%20cervical%20adenocarcinoma%20was%20substantially%20lower%20in%20HIV-positive%20%284%20%25%29%20than%20in%20HIV-negative%20patients%20%2826%20%25%29.%20Most%20HIV-positive%20patients%20%2867%20%25%29%20were%20on%20antiretroviral%20therapy%20at%20cancer%20diagnosis.%20HIV-positive%20patients%20were%20more%20likely%20to%20receive%20radiotherapy%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.90%2C%2095%20%25%20confidence%20interval%20%5BCI%5D%201.05-3.45%29%20or%20chemotherapy%20%28aOR%202.02%2C%2095%20%25CI%200.92-4.43%29%20and%20less%20likely%20to%20undergo%20surgery%20%28aOR%200.53%2C%2095%20%25CI%200.31-0.90%29%20than%20HIV-negative%20patients.%20HIV-positive%20patients%20were%20at%20a%20higher%20risk%20of%20death%20from%20all%20causes%20than%20HIV-negative%20patients%20%28adjusted%20hazard%20ratio%201.52%2C%2095%20%25CI%201.06-2.19%29.%20Other%20factors%20associated%20with%20higher%20all-cause%20mortality%20included%20age%20%26gt%3B%2060%20years%20and%20metastases%20at%20diagnosis.%20CONCLUSIONS%3A%20HIV-positive%20cervical%20cancer%20patients%20in%20South%20Africa%20had%20higher%20all-cause%20mortality%20than%20HIV-negative%20patients%20which%20could%20be%20explained%20by%20differences%20in%20tumour%20progression%2C%20clinical%20care%2C%20and%20HIV-specific%20mortality.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.gore.2022.101069%22%2C%22ISSN%22%3A%222352-5789%20%28Print%29%202352-5789%20%28Electronic%29%202352-5789%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22VIYVS75C%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shamu%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BShamu%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRohner%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChokunonga%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSpoerri%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMandiriri%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cancer%20incidence%20among%20people%20living%20with%20HIV%20in%20Zimbabwe%3A%20A%20record%20linkage%20study.%20%26lt%3Bi%26gt%3BCancer%20Rep%20%28Hoboken%29%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B5%26lt%3B%5C%2Fi%26gt%3B%20%2810%29%2C%20S.%20e1597.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcnr2.1597%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcnr2.1597%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20incidence%20among%20people%20living%20with%20HIV%20in%20Zimbabwe%3A%20A%20record%20linkage%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chokunonga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Spoerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Borok%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20People%20living%20with%20HIV%20%28PLWH%29%20are%20at%20increased%20risk%20of%20developing%20cancer.%20Cancer%20diagnoses%20are%20often%20incompletely%20captured%20at%20antiretroviral%20therapy%20%28ART%29%20clinics.%20AIM%3A%20To%20estimate%20the%20incidence%20and%20explore%20risk%20factors%20of%20cancer%20in%20a%20cohort%20of%20PLWH%20in%20Harare%20using%20probabilistic%20record%20linkage%20%28PRL%29.%20METHODS%3A%20We%20conducted%20a%20retrospective%20cohort%20study%20that%20included%20PLWH%20aged%20%26gt%3B%5C%2F%3D16%20years%20starting%20ART%20between%202004%20and%202017.%20We%20used%20PRL%20to%20match%20records%20from%20the%20Zimbabwe%20National%20Cancer%20Registry%20%28ZNCR%29%20with%20electronic%20medical%20records%20from%20an%20ART%20clinic%20in%20Harare%20to%20investigate%20the%20incidence%20of%20cancer%20among%20PLWH%20initiating%20ART.%20We%20matched%20records%20based%20on%20demographic%20data%20followed%20by%20manual%20clerical%20review.%20We%20followed%20PLWH%20up%20until%20first%20cancer%20diagnosis%2C%20death%2C%20loss%20to%20follow-up%2C%20or%2031%20December%202017%2C%20whichever%20came%20first.%20RESULTS%3A%20We%20included%203442%20PLWH%20%2864.9%25%20female%29%20with%2019%20346%20person-years%20%28PY%29%20of%20follow-up.%20Median%20CD4%20count%20at%20ART%20initiation%20was%20169%20cells%5C%2Fmm%283%29%20%28interquartile%20range%20%5BIQR%5D%3A%2082-275%29%2C%20median%20age%20was%2036.6%20years%20%28IQR%3A%2030.6-43.4%29.%20There%20were%2066%20incident%20cancer%20cases%20for%20an%20overall%20incidence%20rate%20of%20341%5C%2F100%20000%20PY%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%20268-434%29.%20Twenty-two%20of%20these%20cases%20were%20recorded%20in%20the%20ZNCR%20only.%20The%20most%20common%20cancers%20were%20cervical%20cancer%20%28n%20%3D%2016%3B%20123%5C%2F100%20000%20PY%3B%2095%25%20CI%3A%2075-201%29%2C%20Kaposi%20sarcoma%2C%20and%20lymphoma%20%28both%20n%20%3D%2012%3B%2062%5C%2F100%20000%20PY%3B%2095%25%20CI%3A%2035-109%29.%20Cancer%20incidence%20increased%20with%20age%20and%20decreased%20with%20higher%20CD4%20cell%20counts%20at%20ART%20initiation.%20CONCLUSION%3A%20PRL%20was%20key%20to%20correct%20for%20cancer%20under-ascertainment%20in%20this%20cohort.%20The%20most%20common%20cancers%20were%20infection-related%20types%2C%20reinforcing%20the%20role%20of%20early%20HIV%20treatment%2C%20human%20papillomavirus%20vaccination%2C%20and%20cervical%20cancer%20screening%20for%20cancer%20prevention%20in%20this%20setting.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcnr2.1597%22%2C%22ISSN%22%3A%222573-8348%20%28Electronic%29%202573-8348%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22HLEGYTCW%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalua%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKalua%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEgger%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJahn%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChimpandule%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKolola%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study.%20%26lt%3Bi%26gt%3BJ%20Clin%20Epidemiol%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B150%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20116%26%23x2013%3B125.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.06.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20suppression%20was%20maintained%20during%20the%20COVID-19%20pandemic%20in%20Malawi%3A%20a%20program-level%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Kalua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Chimpandule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kolola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Anderegg%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Measures%20introduced%20to%20reduce%20the%20spread%20of%20SARS-CoV-2%20by%20the%20Malawi%20government%20and%20the%20national%20HIV%20care%20program%20might%20have%20compromised%20treatment%20outcomes%20of%20patients%20living%20with%20HIV%20on%20antiretroviral%20therapy%20%28ART%29.%20We%20studied%20viral%20load%20%28VL%29%20outcomes%20before%20and%20during%20the%20COVID-19%20epidemic%20in%20Malawi.%20METHODS%3A%20In%20this%20population-based%20cohort%20study%2C%20we%20included%20all%20routine%20VL%20measurements%20collected%20from%20July%202019%20to%20December%202020%20in%20about%20650%20ART%20clinics%20in%20Malawi.%20We%20examined%20differences%20between%20pandemic%20periods%20%28before%5C%2Fduring%20COVID-19%29%20for%20i%29%20VL%20monitoring%2C%20and%20ii%29%20VL%20suppression%20%28VLS%3A%20%26lt%3B1%2C000%20copies%5C%2Fml%29.%20For%20i%29%20we%20studied%20the%20number%20of%20VL%20measurements%20over%20time%20and%20assessed%20predictors%20of%20missed%20measurements%20before%20and%20during%20COVID-19%20in%20logistic%20regression%20models.%20For%20ii%29%20we%20estimated%20the%20odds%20of%20VLS%20before%20and%20during%20the%20COVID-19%20epidemic%20stratified%20by%20treatment%20regimen%20using%20generalized%20estimation%20equations%20adjusted%20for%20age%2C%20sex%2C%20time%20on%20ART%2C%20and%20type%20of%20biological%20sample.%20We%20imputed%20missing%20treatment%20regimens%20by%20population-calibrated%20multiple%20imputation.%20RESULTS%3A%20We%20included%20607%2C894%20routine%20VL%20samples%20from%20556%2C281%20patients.%20VL%20testing%20declined%20during%20COVID-19%20%28243%2C729%3B%2040%25%29%20compared%20to%20before%20COVID-19%20%28365%2C265%3B%2060%25%29%2C%20but%20predictors%20of%20missing%20tests%20were%20similar%20in%20the%20two%20periods.%20VLS%20rates%20increased%20slightly%20from%2093%25%20before%20to%2094%25%20during%20COVID-19.%20Compared%20to%20before%20COVID-19%2C%20the%20odds%20of%20VLS%20increased%20during%20COVID-19%20for%20patients%20on%20protease%20inhibitor-based%20%28PI%29%20regimens%20%28adjusted%20odds%20ratio%20%5BaOR%5D%201.22%2C%2095%25%20CI%3A%200.99-1.49%29%20and%20for%20patients%20on%20integrase%20strand%20transfer%20inhibitor-based%20%28INSTI%29%20regimens%20%28aOR%201.10%2C%2095%25%20CI%3A%201.03-1.17%29.%20There%20was%20no%20difference%20in%20VLS%20between%20the%20two%20periods%20among%20patients%20on%20nonnucleoside%20reverse%20transcriptase%20inhibitor-based%20%28NNRTI%29%20regimens.%20VLS%20varied%20by%20age%2C%20sex%2C%20regimen%2C%20and%20duration%20on%20ART%2C%20ranging%20from%2045.1%25%20%2895%25%20CI%2040.3-50.0%25%29%20to%2097.2%25%20%2895%25%20CI%2096.9-97.4%25%29.%20CONCLUSION%3A%20There%20was%20a%20significant%20decline%20in%20VL%20monitoring%20during%20COVID-19%2C%20but%20we%20did%20not%20find%20clear%20evidence%20that%20the%20pandemic%20reduced%20VL%20suppression%20rates.%20Routine%20scheduled%20VL%20monitoring%2C%20targeted%20adherence%20support%2C%20and%20timely%20regimen%20switches%20for%20patients%20with%20treatment%20failure%20remain%20critical%20to%20improving%20VLS.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jclinepi.2022.06.019%22%2C%22ISSN%22%3A%221878-5921%20%28Electronic%29%200895-4356%20%28Print%29%200895-4356%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A20%3A46Z%22%7D%7D%2C%7B%22key%22%3A%224YA8ZK3V%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kubjane%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKubjane%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BOsman%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBoulle%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%20%26amp%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJohnson%2C%20L.%20F.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20The%20impact%20of%20HIV%20and%20tuberculosis%20interventions%20on%20South%20African%20adult%20tuberculosis%20trends%2C%201990-2019%3A%20a%20mathematical%20modeling%20analysis.%20%26lt%3Bi%26gt%3BInt%20J%20Infect%20Dis%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B122%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20811%26%23x2013%3B819.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.07.047%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.07.047%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20impact%20of%20HIV%20and%20tuberculosis%20interventions%20on%20South%20African%20adult%20tuberculosis%20trends%2C%201990-2019%3A%20a%20mathematical%20modeling%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kubjane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20quantify%20the%20South%20African%20adult%20tuberculosis%20%28TB%29%20incidence%20and%20mortality%20attributable%20to%20HIV%20between%201990%20and%202019%20and%20to%20estimate%20the%20reduction%20in%20TB%20incidence%20due%20to%20directly%20observed%20therapy%2C%20antiretroviral%20therapy%20%28ART%29%2C%20isoniazid%20preventive%20therapy%2C%20increased%20TB%20screening%2C%20and%20Xpert%20MTB%5C%2FRIF.%20METHODS%3A%20We%20developed%20a%20dynamic%20TB%20transmission%20model%20for%20South%20Africa.%20A%20Bayesian%20approach%20was%20used%20to%20calibrate%20the%20model%20to%20South%20African-specific%20data%20sources.%20Counterfactual%20scenarios%20were%20simulated%20to%20estimate%20TB%20incidence%20and%20mortality%20attributable%20to%20HIV%20and%20the%20impact%20of%20interventions%20on%20TB%20incidence.%20RESULTS%3A%20Between%201990%20and%202019%2C%208.8%20million%20%2895%25%20confidence%20interval%20%5BCI%5D%208.3-9.3%20million%29%20individuals%20developed%20TB%2C%20and%202.1%20million%20%2895%25%20CI%202.0-2.2%20million%29%20died%20from%20TB.%20A%20total%20of%2055%25%20and%2069%25%20of%20TB%20cases%20and%20mortality%20were%20due%20to%20HIV%2C%20respectively.%20Overall%2C%20TB%20screening%20and%20ART%20substantially%20reduced%20TB%20incidence%20by%2028.2%25%20%2895%25%20CI%2026.4-29.8%25%29%20and%2020.0%25%20%2895%25%20CI%2019.2-20.7%25%29%2C%20respectively%2C%20in%202019%3B%20other%20interventions%20had%20minor%20impacts.%20CONCLUSION%3A%20HIV%20has%20dramatically%20increased%20TB%20incidence%20and%20mortality%20in%20South%20Africa.%20The%20provision%20of%20ART%20and%20intensification%20of%20TB%20screening%20explained%20most%20recent%20declines%20in%20TB%20incidence.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.07.047%22%2C%22ISSN%22%3A%221878-3511%20%28Electronic%29%201201-9712%20%28Print%29%201201-9712%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22YNT7B8LY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wada%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BWada%2C%20P.%20Y.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKim%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJayathilake%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDuda%2C%20S.%20N.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAbo%2C%20Y.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016.%20%26lt%3Bi%26gt%3BAIDS%20Patient%20Care%20STDS%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B36%26lt%3B%5C%2Fi%26gt%3B%20%289%29%2C%20S.%20343%26%23x2013%3B355.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20Y.%22%2C%22lastName%22%3A%22Wada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Abo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%20J.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22Retention%20in%20care%20%28RIC%29%20reduces%20HIV%20transmission%20and%20associated%20morbidity%20and%20mortality.%20We%20examined%20whether%20delivery%20of%20comprehensive%20services%20influenced%20individual%20RIC%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20network.%20We%20collected%20site%20data%20through%20IeDEA%20assessments%201.0%20%282000-2009%29%20and%202.0%20%282010-2016%29.%20Each%20site%20received%20a%20comprehensiveness%20score%20for%20service%20availability%20%281%20%3D%20present%2C%200%20%3D%20absent%29%2C%20with%20tallies%20ranging%20from%200%20to%207.%20We%20obtained%20individual-level%20cohort%20data%20for%20adults%20with%20at%20least%20one%20visit%20from%202000%20to%202016%20at%20sites%20responding%20to%20either%20assessment.%20Person-time%20was%20recorded%20annually%2C%20with%20RIC%20defined%20as%20completing%20two%20visits%20at%20least%2090%20days%20apart%20in%20each%20calendar%20year.%20Multivariable%20modified%20Poisson%20regression%20clustered%20by%20site%20yielded%20risk%20ratios%20and%20predicted%20probabilities%20for%20individual%20RIC%20by%20comprehensiveness.%20Among%20347%2C060%20individuals%20in%20care%20at%20122%20sites%20with%201%2C619%2C558%20person-years%20of%20follow-up%2C%2069.8%25%20of%20person-time%20was%20retained%20in%20care%2C%20varying%20by%20region%20from%2053.8%25%20%28Asia-Pacific%29%20to%2082.7%25%20%28East%20Africa%29%3B%20RIC%20improved%20by%20about%202%25%20per%20year%20from%202000%20to%202016%20%28p%20%3D%200.012%29.%20Every%20site%20provided%20CD4%28%2B%29%20count%20testing%2C%20and%20%26gt%3B90%25%20of%20individuals%20received%20care%20at%20sites%20that%20provided%20combination%20antiretroviral%20therapy%20adherence%20measures%2C%20prevention%20of%20mother-to-child%20transmission%2C%20tuberculosis%20screening%2C%20HIV-related%20prevention%2C%20and%20community%20tracing%20services.%20In%20adjusted%20models%2C%20individuals%20at%20sites%20with%20more%20comprehensive%20services%20had%20higher%20probabilities%20of%20RIC%20%280.71%2C%200.74%2C%20and%200.83%20for%20scores%205%2C%206%2C%20and%207%2C%20respectively%3B%20p%20%3D%200.019%29.%20Within%20IeDEA%2C%20greater%20site-level%20comprehensiveness%20of%20services%20was%20associated%20with%20improved%20individual%20RIC.%20Much%20work%20remains%20in%20exploring%20this%20relationship%2C%20which%20may%20inform%20HIV%20clinical%20practice%20and%20health%20systems%20planning.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fapc.2022.0042%22%2C%22ISSN%22%3A%221557-7449%20%28Electronic%29%201087-2914%20%28Print%29%201087-2914%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A28%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22LKS2Q8F6%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Edmonds%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEdmonds%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBrazier%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMusick%2C%20B.%20S.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BYotebieng%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHumphrey%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Clinical%20and%20programmatic%20outcomes%20of%20HIV-exposed%20infants%20enrolled%20in%20care%20at%20geographically%20diverse%20clinics%2C%201997-2021%3A%20A%20cohort%20study.%20%26lt%3Bi%26gt%3BPLoS%20Med%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B19%26lt%3B%5C%2Fi%26gt%3B%20%289%29%2C%20S.%20e1004089.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004089%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004089%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20programmatic%20outcomes%20of%20HIV-exposed%20infants%20enrolled%20in%20care%20at%20geographically%20diverse%20clinics%2C%201997-2021%3A%20A%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20L.%22%2C%22lastName%22%3A%22Abuogi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Keiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Msukwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22IeDea%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Marie-Louise%22%2C%22lastName%22%3A%22Newell%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Although%201.3%20million%20women%20with%20HIV%20give%20birth%20annually%2C%20care%20and%20outcomes%20for%20HIV-exposed%20infants%20remain%20incompletely%20understood.%20We%20analyzed%20programmatic%20and%20health%20indicators%20in%20a%20large%2C%20multidecade%20global%20dataset%20of%20linked%20mother-infant%20records%20from%20clinics%20and%20programs%20associated%20with%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20METHODS%20AND%20FINDINGS%3A%20HIV-exposed%20infants%20were%20eligible%20for%20this%20retrospective%20cohort%20analysis%20if%20enrolled%20at%20%26lt%3B18%20months%20at%20198%20clinics%20in%2010%20countries%20across%205%20IeDEA%20regions%3A%20East%20Africa%20%28EA%29%2C%20Central%20Africa%20%28CA%29%2C%20West%20Africa%20%28WA%29%2C%20Southern%20Africa%20%28SA%29%2C%20and%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20%28CCASAnet%29.%20We%20estimated%20cumulative%20incidences%20of%20DNA%20PCR%20testing%2C%20loss%20to%20follow-up%20%28LTFU%29%2C%20HIV%20diagnosis%2C%20and%20death%20through%2024%20months%20of%20age%20using%20proportional%20subdistribution%20hazard%20models%20accounting%20for%20competing%20risks.%20Competing%20risks%20were%20transfer%2C%20care%20withdrawal%2C%20and%20confirmation%20of%20negative%20HIV%20status%2C%20along%20with%20LTFU%20and%20death%2C%20when%20not%20the%20outcome%20of%20interest.%20In%20CA%20and%20EA%2C%20we%20quantified%20associations%20between%20maternal%5C%2Finfant%20characteristics%20and%20each%20outcome.%20A%20total%20of%2082%2C067%20infants%20%2847%2C300%20EA%2C%2010%2C699%20CA%2C%206%2C503%20WA%2C%2015%2C770%20SA%2C%201%2C795%20CCASAnet%29%20born%20from%201997%20to%202021%20were%20included.%20Maternal%20antiretroviral%20therapy%20%28ART%29%20use%20during%20pregnancy%20ranged%20from%2065.6%25%20%28CCASAnet%29%20to%2089.5%25%20%28EA%29%2C%20with%20improvements%20in%20all%20regions%20over%20time.%20Twenty-four-month%20cumulative%20incidences%20varied%20widely%20across%20regions%2C%20ranging%20from%2012.3%25%20%2895%25%20confidence%20limit%20%5BCL%5D%2C%2011.2%25%2C13.5%25%29%20in%20WA%20to%2094.8%25%20%2895%25%20CL%2C%2094.6%25%2C95.1%25%29%20in%20EA%20for%20DNA%20PCR%20testing%3B%2056.2%25%20%2895%25%20CL%2C%2055.2%25%2C57.1%25%29%20in%20EA%20to%2098.5%25%20%2895%25%20CL%2C%2098.3%25%2C98.7%25%29%20in%20WA%20for%20LTFU%3B%201.9%25%20%2895%25%20CL%2C%201.6%25%2C2.3%25%29%20in%20WA%20to%2010.3%25%20%2895%25%20CL%2C%209.7%25%2C10.9%25%29%20in%20EA%20for%20HIV%20diagnosis%3B%20and%200.5%25%20%2895%25%20CL%2C%200.2%25%2C1.0%25%29%20in%20CCASAnet%20to%204.7%25%20%2895%25%20CL%2C%204.4%25%2C5.0%25%29%20in%20EA%20for%20death.%20Although%20infant%20retention%20did%20not%20improve%2C%20HIV%20diagnosis%20and%20death%20decreased%20over%20time%2C%20and%20in%20EA%2C%20the%20cumulative%20incidence%20of%20HIV%20diagnosis%20decreased%20substantially%2C%20declining%20to%202.9%25%20%2895%25%20CL%2C%201.5%25%2C5.4%25%29%20in%202020.%20Maternal%20ART%20was%20associated%20with%20decreased%20infant%20mortality%20%28subdistribution%20hazard%20ratio%20%5BsdHR%5D%2C%200.65%3B%2095%25%20CL%2C%200.47%2C0.91%20in%20EA%2C%20and%20sdHR%2C%200.51%3B%2095%25%20CL%2C%200.36%2C0.74%20in%20CA%29%20and%20HIV%20diagnosis%20%28sdHR%2C%200.40%3B%2095%25%20CL%2C%200.31%2C0.50%20in%20EA%2C%20and%20sdHR%2C%200.41%3B%2095%25%20CL%2C%200.31%2C0.54%20in%20CA%29.%20Study%20limitations%20include%20potential%20misclassification%20of%20outcomes%20in%20real-world%20service%20delivery%20data%20and%20possible%20nonrepresentativeness%20of%20IeDEA%20sites%20and%20the%20population%20of%20HIV-exposed%20infants%20they%20serve.%20CONCLUSIONS%3A%20While%20there%20was%20marked%20regional%20and%20temporal%20heterogeneity%20in%20clinical%20and%20programmatic%20outcomes%2C%20infant%20LTFU%20was%20high%20across%20all%20regions%20and%20time%20periods.%20Further%20efforts%20are%20needed%20to%20keep%20HIV-exposed%20infants%20in%20care%20to%20receive%20essential%20services%20to%20reduce%20HIV%20infection%20and%20mortality.%22%2C%22date%22%3A%22Sep%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004089%22%2C%22ISSN%22%3A%221549-1676%20%28Electronic%29%201549-1277%20%28Print%29%201549-1277%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A17%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22T3VRSJI7%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Asangbeh-Kerman%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAsangbeh-Kerman%2C%20S.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavidovic%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTaghavi%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKachingwe%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRammipi%2C%20K.%20M.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies.%20%26lt%3Bi%26gt%3BBMC%20Public%20Health%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B22%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%201530.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-022-13827-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20prevention%20in%20countries%20with%20the%20highest%20HIV%20prevalence%3A%20a%20review%20of%20policies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Asangbeh-Kerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Davidovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Kachingwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20M.%22%2C%22lastName%22%3A%22Rammipi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Muzingwani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pascoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mulongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mwanahamuntu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tapela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Akintade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Basu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22X.%22%2C%22lastName%22%3A%22Dlamini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Cervical%20cancer%20%28CC%29%20is%20the%20leading%20cause%20of%20cancer-related%20death%20among%20women%20in%20sub-Saharan%20Africa.%20It%20occurs%20most%20frequently%20in%20women%20living%20with%20HIV%20%28WLHIV%29%20and%20is%20classified%20as%20an%20AIDS-defining%20illness.%20Recent%20World%20Health%20Organisation%20%28WHO%29%20recommendations%20provide%20guidance%20for%20CC%20prevention%20policies%2C%20with%20specifications%20for%20WLHIV.%20We%20systematically%20reviewed%20policies%20for%20CC%20prevention%20and%20control%20in%20sub-Saharan%20countries%20with%20the%20highest%20HIV%20prevalence.%20METHODS%3A%20We%20included%20countries%20with%20an%20HIV%20prevalence%20%26gt%3B%5C%2F%3D%2010%25%20in%202018%20and%20policies%20published%20between%20January%201%28st%29%202010%20and%20March%2031%28st%29%202022.%20We%20searched%20Medline%20via%20PubMed%2C%20the%20international%20cancer%20control%20partnership%20website%20and%20national%20governmental%20websites%20of%20included%20countries%20for%20relevant%20policy%20documents.%20The%20online%20document%20search%20was%20supplemented%20with%20expert%20consultation%20for%20each%20included%20country.%20We%20synthesised%20aspects%20defined%20in%20policies%20for%20HPV%20vaccination%2C%20sex%20education%2C%20condom%20use%2C%20tobacco%20control%2C%20male%20circumcision%2Ccervical%20screening%2C%20diagnosis%20and%20treatment%20of%20cervical%20pre-cancerous%20lesions%20and%20cancer%2C%20monitoring%20mechanisms%20and%20cost%20of%20services%20to%20women%20while%20highlighting%20specificities%20for%20WLHIV.%20RESULTS%3A%20We%20reviewed%2033%20policy%20documents%20from%20nine%20countries.%20All%20included%20countries%20had%20policies%20on%20CC%20prevention%20and%20control%20either%20as%20a%20standalone%20policy%20%2877.8%25%29%2C%20or%20as%20part%20of%20a%20cancer%20or%20non-communicable%20diseases%20policy%20%2822.2%25%29%20or%20both%20%2866.7%25%29.%20Aspects%20of%20HPV%20vaccination%20were%20reported%20in%207%20%2877.8%25%29%20of%20the%209%20countries.%20All%20countries%20%28100%25%29%20planned%20to%20develop%20or%20review%20Information%2C%20Education%20and%20Communication%20%28IEC%29%20materials%20for%20CC%20prevention%20including%20condom%20use%20and%20tobacco%20control.%20Age%20at%20screening%20commencement%20and%20screening%20intervals%20for%20WLHIV%20varied%20across%20countries.%20The%20most%20common%20recommended%20screening%20and%20treatment%20methods%20were%20visual%20inspection%20with%20acetic%20acid%20%28VIA%29%20%2888.9%25%29%2C%20Pap%20smear%20%2877.8%25%29%3B%20cryotherapy%20%28100%25%29%20and%20loop%20electrosurgical%20procedure%20%28LEEP%29%20%2888.9%25%29%20respectively.%20Global%20indicators%20disaggregated%20by%20HIV%20status%20for%20monitoring%20CC%20programs%20were%20rarely%20reported.%20CC%20prevention%20and%20care%20policies%20included%20service%20costs%20at%20various%20stages%20in%20three%20countries%20%2833.3%25%29.%20CONCLUSION%3A%20Considerable%20progress%20has%20been%20made%20in%20policy%20development%20for%20CC%20prevention%20and%20control%20in%20sub%20Saharan%20Africa.%20However%2C%20in%20countries%20with%20a%20high%20HIV%20burden%2C%20there%20is%20need%20to%20tailor%20these%20policies%20to%20respond%20to%20the%20specific%20needs%20of%20WLHIV.%20Countries%20may%20consider%20updating%20policies%20using%20the%20recent%20WHO%20guidelines%20for%20CC%20prevention%2C%20while%20adapting%20them%20to%20context%20realities.%22%2C%22date%22%3A%22Aug%2010%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-022-13827-0%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A38%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22WGGXIKV8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hauser%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHauser%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BGoldstein%2C%20F.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BReichmuth%2C%20M.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKouyos%2C%20R.%20D.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BWandeler%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Acquired%20HIV%20drug%20resistance%20mutations%20on%20first-line%20antiretroviral%20therapy%20in%20Southern%20Africa%3A%20Systematic%20review%20and%20Bayesian%20evidence%20synthesis.%20%26lt%3Bi%26gt%3BJ%20Clin%20Epidemiol%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B148%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20135%26%23x2013%3B145.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.02.005%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jclinepi.2022.02.005%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acquired%20HIV%20drug%20resistance%20mutations%20on%20first-line%20antiretroviral%20therapy%20in%20Southern%20Africa%3A%20Systematic%20review%20and%20Bayesian%20evidence%20synthesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Hauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Goldstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20estimate%20the%20prevalence%20of%20NRTI%20and%20NNRTI%20drug%20resistance%20mutations%20in%20patients%20failing%20NNRTI-based%20ART%20in%20Southern%20Africa.%20STUDY%20DESIGN%3A%20We%20conducted%20a%20systematic%20review%20to%20identify%20studies%20reporting%20drug%20resistance%20mutations%20among%20adult%20people%20living%20with%20HIV%20%28PLWH%29%20who%20experienced%20virological%20failure%20on%20first-line%20NNRTI-based%20ART%20in%20Southern%20Africa.%20We%20used%20a%20Bayesian%20hierarchical%20meta-regression%20model%20to%20synthesize%20the%20evidence%20on%20the%20frequency%20of%20eight%20NRTI-%20and%20seven%20NNRTI-DRMs%20across%20different%20ART%20regimens%2C%20accounting%20for%20ART%20duration%20and%20study%20characteristics.%20RESULTS%3A%20We%20included%2019%20study%20populations%2C%20including%202%2C690%20PLWH.%20Patients%20failing%20first-line%20ART%20including%20emtricitabine%20or%20lamivudine%20showed%20high%20levels%20of%20the%20M184V%5C%2FI%20mutation%20after%202%20years%3A%2075.7%25%20%2895%25%20Credibility%20Interval%20%5BCrI%5D%2061.9%25-88.9%25%29%20if%20combined%20with%20tenofovir%2C%20and%2072.1%25%20%2895%25%20CrI%2056.8%25-85.9%25%29%20with%20zidovudine.%20With%20tenofovir%20disoproxil%20fumarate%2C%20the%20prevalence%20of%20the%20K65R%20mutation%20was%2052.0%25%20%2895%25%20CrI%2032.5%25-76.8%25%29%20at%202%20years.%20On%20efavirenz%2C%20K103%20was%20the%20most%20prevalent%20NNRTI%20resistance%20mutation%20%2857.2%25%2C%2095%25%20CrI%2040.9%25-80.1%25%29%2C%20followed%20by%20V106%20%2846.8%25%2C%2095%25%20CrI%2031.3%25-70.4%25%29.%20CONCLUSIONS%3A%20NRTI%5C%2FNNRTI%20drug%20resistance%20mutations%20are%20common%20in%20patients%20failing%20first-line%20ART%20in%20Southern%20Africa.%20These%20patients%20might%20switch%20to%20dolutegravir-based%20regimen%20with%20compromised%20NRTIs%2C%20which%20could%20impair%20the%20long-term%20efficacy%20of%20ART.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jclinepi.2022.02.005%22%2C%22ISSN%22%3A%221878-5921%20%28Electronic%29%200895-4356%20%28Print%29%200895-4356%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22VZAULTB8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Christ%20et%20al.%22%2C%22parsedDate%22%3A%222022-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChrist%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3Bvan%20Dijk%2C%20J.%20H.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNyandoro%2C%20T.%20Y.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BReichmuth%2C%20M.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKunzekwenyika%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%288%29%2C%20S.%20e25944.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25944%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20and%20experiences%20of%20differentiated%20antiretroviral%20therapy%20delivery%20at%20HIV%20care%20facilities%20in%20rural%20Zimbabwe%3A%20a%20mixed-method%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20H.%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20Y.%22%2C%22lastName%22%3A%22Nyandoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chammartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Wringe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%20in%20Southern%20Africa%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Zimbabwe%20adopted%20differentiated%20HIV%20care%20policies%20in%202015%20to%20promote%20client-centred%20care%20and%20relieve%20strain%20on%20health%20facilities.%20We%20examined%20the%20availability%2C%20experiences%20and%20perceptions%20of%20differentiated%20antiretroviral%20therapy%20%28ART%29%20delivery%20in%20rural%20Zimbabwe%20following%20the%20policy%20adoption.%20METHODS%3A%20We%20undertook%20a%20cross-sectional%20mixed%20methods%20study%20in%20all%20the%2026%20facilities%20providing%20HIV%20care%20in%20a%20rural%20district%20in%20Zimbabwe.%20We%20collected%20quantitative%20data%20about%20ART%20delivery%20and%20visit%20durations%20from%2031%20healthcare%20providers%20and%20a%20purposive%20stratified%20sample%20of%20378%20clients%20obtaining%20ART%20either%20through%20routine%20care%20or%20differentiated%20ART%20delivery%20models.%20We%20performed%2026%20semi-structured%20interviews%20among%20healthcare%20providers%20and%20seven%20focus%20group%20discussions%20%28FGDs%29%20among%20clients%20to%20elicit%20their%20perceptions%20and%20experiences%20of%20ART%20delivery.%20Data%20were%20collected%20in%202019%2C%20with%20one%20follow-up%20FGD%20in%202021.%20We%20analysed%20the%20transcripts%20thematically%2C%20with%20inductive%20coding%2C%20to%20identify%20emerging%20themes.%20RESULTS%3A%20Twenty%20facilities%20%2877%25%29%20offered%20at%20least%20one%20differentiated%20ART%20delivery%20models%2C%20including%20community%20ART%20refill%20groups%20%28CARGs%3B%2013%20facilities%2C%2050%25%29%2C%20fast-track%20refill%20%288%2C%2031%25%29%2C%20family%20refill%20%286%2C%2023%25%29%20or%20club%20refill%20%281%2C%204%25%29.%20Thirteen%20facilities%20%2850%25%29%20offered%20only%20one%20model.%20The%20median%20visit%20duration%20was%2028%20minutes%20%28interquartile%20range%20%5BIQR%5D%3A%2016-62%29.%20Participants%20in%20fast-track%20had%20the%20shortest%20visit%20durations%20%2818%20minutes%2C%20IQR%3A%2011-24%29.%20Confidentiality%20and%20disclosure%20of%20HIV%20status%2C%20travelling%20long%20distances%2C%20travel%20costs%20and%20waiting%20times%20were%20the%20main%20issues%20influencing%20clients%26%23039%3B%20views%20on%20differentiated%20ART%20delivery.%20Fast-track%20refill%20was%20perceived%20as%20the%20preferred%20model%20of%20clients%20for%20its%20limited%20involuntary%20disclosure%20and%20efficiency.%20In%20contrast%2C%20group-%20and%20community-based%20refill%20models%20reduced%20travel%20costs%20but%20were%20felt%20to%20be%20associated%20with%20involuntary%20disclosure%20of%20HIV%20status%2C%20which%20could%20discourage%20clients.%20Healthcare%20providers%20also%20experienced%20an%20additional%20workload%20when%20offering%20facility-based%20group%20models%2C%20such%20as%20CARGs.%20CONCLUSIONS%3A%20Differentiated%20ART%20delivery%20models%20were%20widely%20available%20in%20this%20rural%20setting%2C%20but%20most%20facilities%20did%20not%20offer%20a%20choice%20of%20models%20to%20address%20clients%26%23039%3B%20diverse%20preferences.%20A%20minority%20offered%20fast-track%20refills%2C%20although%20this%20model%20was%20often%20mentioned%20as%20desirable.%20Confidentiality%2C%20travel%20expenses%20and%20client%20waiting%20times%20are%20key%20elements%20to%20consider%20when%20planning%20and%20rolling%20out%20differentiated%20HIV%20care.%22%2C%22date%22%3A%22Aug%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25944%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22XYJZH82A%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davies%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20Mary-Ann%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMorden%2C%20Erna%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRosseau%2C%20Petro%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BArendse%2C%20Juanita%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBam%2C%20Jamy-Lee%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20during%20resurgence%20driven%20by%20Omicron%20lineages%20BA.4%20and%20BA.5%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa.%20%26lt%3Bi%26gt%3BMedRxiv%3A%20The%20Preprint%20Server%20for%20Health%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%202022.06.28.22276983.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.06.28.22276983%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.06.28.22276983%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20during%20resurgence%20driven%20by%20Omicron%20lineages%20BA.4%20and%20BA.5%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erna%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petro%22%2C%22lastName%22%3A%22Rosseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juanita%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamy-Lee%22%2C%22lastName%22%3A%22Bam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Cloete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheryl%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Chetty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Dane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nei-Yuan%22%2C%22lastName%22%3A%22Hsiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehreen%22%2C%22lastName%22%3A%22Hunter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannah%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theuns%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waasila%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saadiq%22%2C%22lastName%22%3A%22Kariem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inneke%22%2C%22lastName%22%3A%22Laenen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sue%22%2C%22lastName%22%3A%22Le%20Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Mahomed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Maughan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graeme%22%2C%22lastName%22%3A%22Meintjes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayanda%22%2C%22lastName%22%3A%22Mnguni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melvin%22%2C%22lastName%22%3A%22Moodley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katy%22%2C%22lastName%22%3A%22Murie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Naude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ntobeko%20A.%20B.%22%2C%22lastName%22%3A%22Ntusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masudah%22%2C%22lastName%22%3A%22Paleker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arifa%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Pienaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfgang%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liezel%22%2C%22lastName%22%3A%22Rossouw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neshaad%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariette%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wesley%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jantjie%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milani%22%2C%22lastName%22%3A%22Wolmarans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20aimed%20to%20compare%20clinical%20severity%20of%20Omicron%20BA.4%5C%2FBA.5%20infection%20with%20BA.1%20and%20earlier%20variant%20infections%20among%20laboratory-confirmed%20SARS-CoV-2%20cases%20in%20the%20Western%20Cape%2C%20South%20Africa%2C%20using%20timing%20of%20infection%20to%20infer%20the%20lineage%5C%2Fvariant%20causing%20infection.%5CnMETHODS%3A%20We%20included%20public%20sector%20patients%20aged%20%5Cu00e2%5Cu2030%5Cu00a520%20years%20with%20laboratory-confirmed%20COVID-19%20between%201-21%20May%202022%20%28BA.4%5C%2FBA.5%20wave%29%20and%20equivalent%20prior%20wave%20periods.%20We%20compared%20the%20risk%20between%20waves%20of%20%28i%29%20death%20and%20%28ii%29%20severe%20hospitalization%5C%2Fdeath%20%28all%20within%2021%20days%20of%20diagnosis%29%20using%20Cox%20regression%20adjusted%20for%20demographics%2C%20comorbidities%2C%20admission%20pressure%2C%20vaccination%20and%20prior%20infection.%5CnRESULTS%3A%20Among%203%2C793%20patients%20from%20the%20BA.4%5C%2FBA.5%20wave%20and%20190%2C836%20patients%20from%20previous%20waves%20the%20risk%20of%20severe%20hospitalization%5C%2Fdeath%20was%20similar%20in%20the%20BA.4%5C%2FBA.5%20and%20BA.1%20waves%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%201.12%3B%2095%25%20confidence%20interval%20%5BCI%5D%200.93%3B%201.34%29.%20Both%20Omicron%20waves%20had%20lower%20risk%20of%20severe%20outcomes%20than%20previous%20waves.%20Prior%20infection%20%28aHR%200.29%2C%2095%25%20CI%200.24%3B%200.36%29%20and%20vaccination%20%28aHR%200.17%3B%2095%25%20CI%200.07%3B%200.40%20for%20boosted%20vs.%20no%20vaccine%29%20were%20protective.%5CnCONCLUSION%3A%20Disease%20severity%20was%20similar%20amongst%20diagnosed%20COVID-19%20cases%20in%20the%20BA.4%5C%2FBA.5%20and%20BA.1%20periods%20in%20the%20context%20of%20growing%20immunity%20against%20SARS-CoV-2%20due%20to%20prior%20infection%20and%20vaccination%2C%20both%20of%20which%20were%20strongly%20protective.%22%2C%22date%22%3A%222022-07-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2022.06.28.22276983%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222025-03-17T16%3A19%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22I7VS56EA%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lewis%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BLewis%2C%20J.%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BStephens%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMusick%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBrown%2C%20S.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMalateste%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20The%20IeDEA%20harmonist%20data%20toolkit%3A%20A%20data%20quality%20and%20data%20sharing%20solution%20for%20a%20global%20HIV%20research%20consortium.%20%26lt%3Bi%26gt%3BJ%20Biomed%20Inform%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B131%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20104110.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbi.2022.104110%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbi.2022.104110%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20IeDEA%20harmonist%20data%20toolkit%3A%20A%20data%20quality%20and%20data%20sharing%20solution%20for%20a%20global%20HIV%20research%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Stephens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ha%20Dao%20Ostinelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%22%2C%22lastName%22%3A%22on%20the%20behalf%20of%20le%22%7D%5D%2C%22abstractNote%22%3A%22We%20describe%20the%20design%2C%20implementation%2C%20and%20impact%20of%20a%20data%20harmonization%2C%20data%20quality%20checking%2C%20and%20dynamic%20report%20generation%20application%20in%20an%20international%20observational%20HIV%20research%20network.%20The%20IeDEA%20Harmonist%20Data%20Toolkit%20is%20a%20web-based%20application%20written%20in%20the%20open%20source%20programming%20language%20R%2C%20employs%20the%20R%5C%2FShiny%20and%20RMarkdown%20packages%2C%20and%20leverages%20the%20REDCap%20data%20collection%20platform%20for%20data%20model%20definition%20and%20user%20authentication.%20The%20Toolkit%20performs%20data%20quality%20checks%20on%20uploaded%20datasets%2C%20checks%20for%20conformance%20with%20the%20network%26%23039%3Bs%20common%20data%20model%2C%20displays%20the%20results%20both%20interactively%20and%20in%20downloadable%20reports%2C%20and%20stores%20approved%20datasets%20in%20secure%20cloud%20storage%20for%20retrieval%20by%20the%20requesting%20investigator.%20Including%20stakeholders%20and%20users%20in%20the%20design%20process%20was%20key%20to%20the%20successful%20adoption%20of%20the%20application.%20A%20survey%20of%20regional%20data%20managers%20as%20well%20as%20initial%20usage%20metrics%20indicate%20that%20the%20Toolkit%20saves%20time%20and%20results%20in%20improved%20data%20quality%2C%20with%20a%2061%25%20mean%20reduction%20in%20the%20number%20of%20error%20records%20in%20a%20dataset.%20The%20generalized%20application%20design%20allows%20the%20Toolkit%20to%20be%20easily%20adapted%20to%20other%20research%20networks.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbi.2022.104110%22%2C%22ISSN%22%3A%221532-0480%20%28Electronic%29%201532-0464%20%28Print%29%201532-0464%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A30%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22U2PE9QVY%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chihota%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChihota%2C%20B.%20V.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRiebensahm%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuula%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSinkala%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChilengi%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20%26lt%3Bi%26gt%3BBMJ%20Open%20Gastroenterol%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B9%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%20e000945.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgast-2022-000945%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Liver%20steatosis%20and%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Chilengi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mulenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bosomprah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rauch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Berzigotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20southern%20Africa%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20growing%20importance%20of%20non-communicable%20diseases%20%28NCDs%29%20and%20high%20HIV%20prevalence%20in%20urban%20African%20settings%20may%20increase%20the%20burden%20of%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20%28MAFLD%29.%20We%20assessed%20liver%20steatosis%20among%20HIV-positive%20and%20negative%20adults%20in%20urban%20Zambia.%20METHODS%3A%20Adults%2030%20years%20and%20older%20who%20were%20newly%20diagnosed%20with%20HIV%2C%20or%20tested%20HIV-negative%20at%20two%20primary%20care%20clinics%20in%20Lusaka%2C%20Zambia%2C%20were%20assessed%20for%20liver%20steatosis.%20Cardiometabolic%20data%20were%20collected%20through%20comprehensive%20clinical%20and%20laboratory%20assessments.%20Transient%20elastography%20was%20performed%20to%20measure%20controlled-attenuation%20parameter%20%28%26gt%3B%5C%2F%3D248%20dB%5C%2Fm%29.%20We%20used%20multivariable%20logistic%20regression%20models%20to%20determine%20the%20factors%20associated%20with%20the%20presence%20of%20steatosis.%20RESULTS%3A%20We%20enrolled%20381%20patients%2C%20including%20154%20%2840%25%29%20antiretroviral%20therapy-naive%20people%20living%20with%20HIV%20%28PLWH%29%20with%20a%20median%20CD4%2B%20count%20of%20247%20cells%5C%2Fmm%283%29%20and%20a%20mean%20body%20mass%20index%20%28BMI%29%20of%2023.8%20kg%5C%2Fm%282%29.%20Liver%20steatosis%20was%20observed%20in%2010%25%20of%20participants%20overall%20and%20was%20more%20common%20among%20HIV-negative%20adults%20than%20in%20PLWH%20%2815%25%20vs%203%25%29.%20The%20proportion%20of%20patients%20with%20steatosis%20was%2025%25%20among%20obese%20%28BMI%20%26gt%3B%5C%2F%3D30%20kg%5C%2Fm%282%29%29%20participants%2C%2012%25%20among%20those%20overweight%20%28BMI%2025-29.9%20kg%5C%2Fm%282%29%29%2C%20and%207%25%20among%20those%20with%20a%20BMI%20%26lt%3B25%20kg%5C%2Fm%282%29.%20Among%20patients%20with%20a%20fasting%20glucose%20%26gt%3B%5C%2F%3D7%20mmol%5C%2FL%20or%20confirmed%20diabetes%2C%2057%25%20had%20liver%20steatosis.%20In%20multivariable%20analyses%2C%20HIV%20status%20%28adjusted%20odds%20ratio%20%28aOR%29%200.18%2C%2095%25%20CI%200.06%20to%200.53%29%2C%20confirmed%20diabetes%20or%20elevated%20fasting%20glucose%20%28aOR%203.92%2C%2095%25%20CI%201.57%20to%209.78%29%20and%20elevated%20blood%20pressure%20%28aOR%202.95%2C%2095%25%20CI%201.34%20to%206.48%29%20were%20associated%20with%20steatosis.%20The%20association%20between%20BMI%26gt%3B25%20kg%5C%2Fm%282%29%20and%20liver%20steatosis%20was%20attenuated%20after%20adjustment%20for%20potential%20confounders%20%28aOR%201.96%2C%2095%25%20CI%200.88-4.40%29.%20Overall%2C%2021%20%289%25%29%20participants%20without%20HIV%20and%204%20%283%25%29%20with%20HIV%20met%20the%20criteria%20for%20MAFLD.%20Among%20individuals%20with%20liver%20steatosis%2C%2065%25%20%2895%25%20CI%2049%25%20to%2080%25%29%20fulfilled%20criteria%20of%20MAFLD%2C%20whereas%2015%20%2839%25%29%20of%20them%20had%20elevated%20transaminases%20and%203%20%288%25%29%20F2-F4%20fibrosis.%20CONCLUSIONS%3A%20The%20prevalence%20of%20liver%20steatosis%20in%20this%20urban%20cohort%20of%20HIV-positive%20and%20negative%20adults%20in%20Zambia%20was%20low%2C%20despite%20a%20large%20proportion%20of%20patients%20with%20high%20BMI%20and%20central%20obesity.%20Our%20study%20is%20among%20the%20first%20to%20report%20data%20on%20MAFLD%20among%20adults%20in%20Africa%2C%20demonstrating%20that%20metabolic%20risk%20factors%20are%20key%20drivers%20of%20liver%20steatosis%20and%20supporting%20the%20adoption%20of%20the%20criteria%20for%20MAFLD%20in%20African%20populations.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgast-2022-000945%22%2C%22ISSN%22%3A%222054-4774%20%28Print%29%202054-4774%20%28Electronic%29%202054-4774%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A29Z%22%7D%7D%2C%7B%22key%22%3A%228N68RLVP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Romo%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A10%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRomo%2C%20M.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBrazier%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMahambou-Nsonde%2C%20D.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDe%20Waal%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSekaggya-Wiltshire%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%287%29%2C%20S.%20e25961.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25961%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-world%20use%20and%20outcomes%20of%20dolutegravir-containing%20antiretroviral%20therapy%20in%20HIV%20and%20tuberculosis%20co-infection%3A%20a%20site%20survey%20and%20cohort%20study%20in%20sub-Saharan%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Romo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Mahambou-Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22De%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Sekaggya-Wiltshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20R.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dzudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Rafael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%20C.%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20S.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dolutegravir%20is%20being%20scaled%20up%20globally%20as%20part%20of%20antiretroviral%20therapy%20%28ART%29%2C%20but%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%2C%20its%20use%20is%20complicated%20by%20a%20drug-drug%20interaction%20with%20rifampicin%20requiring%20an%20additional%20daily%20dose%20of%20dolutegravir.%20This%20represents%20a%20disadvantage%20over%20efavirenz%2C%20which%20does%20not%20have%20a%20major%20drug-drug%20interaction%20with%20rifampicin.%20We%20sought%20to%20describe%20HIV%20clinic%20practices%20for%20prescribing%20concomitant%20dolutegravir%20and%20rifampicin%2C%20and%20characterize%20virologic%20outcomes%20among%20patients%20with%20tuberculosis%20co-infection%20receiving%20dolutegravir%20or%20efavirenz.%20METHODS%3A%20Within%20the%20four%20sub-Saharan%20Africa%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%2C%20we%20conducted%20a%20site%20survey%20%282021%29%20and%20a%20cohort%20study%20%282015-2021%29.%20The%20cohort%20study%20used%20routine%20clinical%20data%20and%20included%20patients%20newly%20initiating%20or%20already%20receiving%20dolutegravir%20or%20efavirenz%20at%20the%20time%20of%20tuberculosis%20diagnosis.%20Patients%20were%20followed%20from%20tuberculosis%20diagnosis%20until%20viral%20suppression%20%28%26lt%3B1000%20copies%5C%2Fml%29%2C%20a%20competing%20event%20%28switching%20ART%20regimen%3B%20loss%20to%20program%5C%2Fdeath%29%20or%20administrative%20censoring%20at%2012%20months.%20RESULTS%3A%20In%20the%20survey%2C%2086%20of%2090%20%2896%25%29%20HIV%20clinics%20in%2018%20countries%20reported%20prescribing%20dolutegravir%20to%20patients%20who%20were%20receiving%20rifampicin%20as%20part%20of%20tuberculosis%20treatment%2C%20with%2077%20%2890%25%29%20reporting%20that%20they%20use%20twice-daily%20dosing%20of%20dolutegravir%2C%20of%20which%2074%20%2896%25%29%20reported%20having%2050%20mg%20tablets%20available%20to%20accommodate%20twice-daily%20dosing.%20The%20cohort%20study%20included%203563%20patients%20in%2011%20countries%2C%20with%2067%25%20newly%20or%20recently%20initiating%20ART.%20Among%20patients%20receiving%20dolutegravir%20%28n%20%3D%20465%29%2C%20the%20cumulative%20incidence%20of%20viral%20suppression%20was%2058.9%25%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2054.3-63.3%25%29%2C%20switching%20ART%20regimen%20was%204.1%25%20%2895%25%20CI%3A%202.6-6.2%25%29%20and%20loss%20to%20program%5C%2Fdeath%20was%2023.4%25%20%2895%25%20CI%3A%2019.7-27.4%25%29.%20Patients%20receiving%20dolutegravir%20had%20improved%20viral%20suppression%20compared%20with%20patients%20receiving%20efavirenz%20who%20had%20a%20tuberculosis%20diagnosis%20before%20site%20dolutegravir%20availability%20%28adjusted%20subdistribution%20hazard%20ratio%20%5BaSHR%5D%3A%201.47%2C%2095%25%20CI%3A%201.28-1.68%29%20and%20after%20site%20dolutegravir%20availability%20%28aSHR%201.28%2C%2095%25%20CI%3A%201.08-1.51%29.%20CONCLUSIONS%3A%20At%20a%20programmatic%20level%2C%20dolutegravir%20was%20being%20widely%20prescribed%20in%20sub-Saharan%20Africa%20for%20people%20with%20HIV%20and%20tuberculosis%20co-infection%20with%20a%20dose%20adjustment%20for%20the%20drug-drug%20interaction%20with%20rifampicin.%20Despite%20this%20more%20complex%20regimen%2C%20our%20cohort%20study%20revealed%20that%20dolutegravir%20did%20not%20negatively%20impact%20viral%20suppression.%22%2C%22date%22%3A%22Jul%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25961%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A25%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22JKGXEYY8%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalk%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-29%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKalk%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHeekes%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSlogrove%2C%20A.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BPhelanyane%2C%20F.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20M.%20A.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29.%20%26lt%3Bi%26gt%3BBMJ%20Open%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%20%286%29%2C%20S.%20e060205.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-060205%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cohort%20profile%3A%20the%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28WCPER%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kroon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Petro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Fieggen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Rhoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gebhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Osman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20Western%20Cape%20Pregnancy%20Exposure%20Registry%20%28PER%29%20was%20established%20at%20two%20public%20sector%20healthcare%20sentinel%20sites%20in%20the%20Western%20Cape%20province%2C%20South%20Africa%2C%20to%20provide%20ongoing%20surveillance%20of%20drug%20exposures%20in%20pregnancy%20and%20associations%20with%20pregnancy%20outcomes.%20PARTICIPANTS%3A%20Established%20in%202016%2C%20all%20women%20attending%20their%20first%20antenatal%20visit%20at%20primary%20care%20obstetric%20facilities%20were%20enrolled%20and%20followed%20to%20pregnancy%20outcome%20regardless%20of%20the%20site%20%28ie%2C%20primary%2C%20secondary%2C%20tertiary%20facility%29.%20Routine%20operational%20obstetric%20and%20medical%20data%20are%20digitised%20from%20the%20clinical%20stationery%20at%20the%20healthcare%20facilities.%20Data%20collection%20has%20been%20integrated%20into%20existing%20services%20and%20information%20platforms%20and%20supports%20routine%20operations.%20The%20PER%20is%20situated%20within%20the%20Provincial%20Health%20Data%20Centre%2C%20an%20information%20exchange%20that%20harmonises%20and%20consolidates%20all%20health-related%20electronic%20data%20in%20the%20province.%20Data%20are%20contributed%20via%20linkage%20across%20a%20unique%20identifier.%20This%20relationship%20limits%20the%20missing%20data%20in%20the%20PER%2C%20allows%20validation%20and%20avoids%20misclassification%20in%20the%20population-level%20data%20set.%20FINDINGS%20TO%20DATE%3A%20Approximately%205000%20and%203500%20pregnant%20women%20enter%20the%20data%20set%20annually%20at%20the%20urban%20and%20rural%20sites%2C%20respectively.%20As%20of%20August%202021%2C%20%26gt%3B30%20000%20pregnancies%20have%20been%20recorded%20and%20outcomes%20have%20been%20determined%20for%2093%25.%20Analysis%20of%20key%20obstetric%20and%20neonatal%20health%20indicators%20derived%20from%20the%20PER%20are%20consistent%20with%20the%20aggregate%20data%20in%20the%20District%20Health%20Information%20System.%20FUTURE%20PLANS%3A%20This%20represents%20significant%20infrastructure%2C%20able%20to%20address%20clinical%20and%20epidemiological%20concerns%20in%20a%20low%5C%2Fmiddle-income%20setting.%22%2C%22date%22%3A%22Jun%2029%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-060205%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222025-03-11T14%3A31%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22MEWUJS5K%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wettstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BWettstein%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTlali%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJoska%2C%20J.%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCornell%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSkrivankova%2C%20V.%20W.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20The%20effect%20of%20the%20COVID-19%20lockdown%20on%20mental%20health%20care%20use%20in%20South%20Africa%3A%20an%20interrupted%20time-series%20analysis.%20%26lt%3Bi%26gt%3BEpidemiol%20Psychiatr%20Sci%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B31%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20e43.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS2045796022000270%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS2045796022000270%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20the%20COVID-19%20lockdown%20on%20mental%20health%20care%20use%20in%20South%20Africa%3A%20an%20interrupted%20time-series%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Wettstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Joska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20W.%22%2C%22lastName%22%3A%22Skrivankova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Seedat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Mouton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20L.%22%2C%22lastName%22%3A%22van%20den%20Heuvel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20The%20coronavirus%20disease%202019%20%28COVID-19%29%20pandemic%20and%20ensuing%20restrictions%20have%20negatively%20affected%20the%20mental%20health%20and%20well-being%20of%20the%20general%20population%2C%20and%20there%20is%20increasing%20evidence%20suggesting%20that%20lockdowns%20have%20led%20to%20a%20disruption%20of%20health%20services.%20In%20March%202020%2C%20South%20Africa%20introduced%20a%20lockdown%20in%20response%20to%20the%20COVID-19%20pandemic%2C%20entailing%20the%20suspension%20of%20all%20non-essential%20activities%20and%20a%20complete%20ban%20of%20tobacco%20and%20alcohol%20sales.%20We%20studied%20the%20effect%20of%20the%20lockdown%20on%20mental%20health%20care%20utilisation%20rates%20in%20private-sector%20care%20in%20South%20Africa.%20METHODS%3A%20We%20conducted%20an%20interrupted%20time-series%20analysis%20using%20insurance%20claims%20from%201%20January%202017%20to%201%20June%202020%20of%20beneficiaries%2018%20years%20or%20older%20from%20a%20large%20private%20sector%20medical%20insurance%20scheme.%20We%20calculated%20weekly%20outpatient%20consultation%20and%20hospital%20admission%20rates%20for%20organic%20mental%20disorders%2C%20substance%20use%20disorders%2C%20serious%20mental%20disorders%2C%20depression%2C%20anxiety%2C%20other%20mental%20disorders%2C%20any%20mental%20disorder%20and%20alcohol%20withdrawal%20syndrome.%20We%20calculated%20adjusted%20odds%20ratios%20%28OR%29%20for%20the%20effect%20of%20the%20lockdown%20on%20weekly%20outpatient%20consultation%20and%20hospital%20admission%20rates%20and%20the%20weekly%20change%20in%20rates%20during%20the%20lockdown%20until%201%20June%202020.%20RESULTS%3A%20710%20367%20persons%20were%20followed%20up%20for%20a%20median%20of%20153%20weeks.%20Hospital%20admission%20rates%20%28OR%200.38%3B%2095%25%20confidence%20interval%20%28CI%29%200.33-0.44%29%20and%20outpatient%20consultation%20rates%20%28OR%200.74%3B%2095%25%20CI%200.63-0.87%29%20for%20any%20mental%20disorder%20decreased%20substantially%20after%20the%20introduction%20of%20the%20lockdown%20and%20did%20not%20recover%20to%20pre-lockdown%20levels%20by%201%20June%202020.%20Health%20care%20utilisation%20rates%20for%20alcohol%20withdrawal%20syndrome%20doubled%20after%20the%20introduction%20of%20the%20lockdown%2C%20but%20the%20statistical%20uncertainty%20around%20the%20estimates%20was%20large%20%28OR%202.24%3B%2095%25%20CI%200.69-7.24%29.%20CONCLUSIONS%3A%20Mental%20health%20care%20utilisation%20rates%20for%20inpatient%20and%20outpatient%20services%20decreased%20substantially%20after%20the%20introduction%20of%20the%20lockdown.%20Hospital%20admissions%20and%20outpatient%20consultations%20for%20alcohol%20withdrawal%20syndrome%20increased%20after%20the%20introduction%20of%20the%20lockdown%2C%20but%20statistical%20uncertainty%20precludes%20strong%20conclusions%20about%20a%20potential%20unintended%20effect%20of%20the%20alcohol%20sales%20ban.%20Governments%20should%20integrate%20strategies%20for%20ensuring%20access%20and%20continuity%20of%20essential%20mental%20health%20services%20during%20lockdowns%20in%20pandemic%20preparedness%20planning.%22%2C%22date%22%3A%22Jun%2015%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1017%5C%2FS2045796022000270%22%2C%22ISSN%22%3A%222045-7979%20%28Electronic%29%202045-7960%20%28Print%29%202045-7960%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22ALEFZH9L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22van%20der%20Hoven%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-03%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3Bvan%20der%20Hoven%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAllen%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCois%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3Bde%20Waal%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMaartens%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment.%20%26lt%3Bi%26gt%3BBMC%20Pregnancy%20Childbirth%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B22%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%20466.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12884-022-04765-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20antenatal%20medicine%20exposures%20in%20South%20African%20women%3A%20a%20comparison%20of%20three%20methods%20of%20ascertainment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22van%20der%20Hoven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Cois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Maartens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Malaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Phelanyane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20the%20absence%20of%20clinical%20trials%2C%20data%20on%20the%20safety%20of%20medicine%20exposures%20in%20pregnancy%20are%20dependent%20on%20observational%20studies%20conducted%20after%20the%20agent%20has%20been%20licensed%20for%20use.%20This%20requires%20an%20accurate%20history%20of%20antenatal%20medicine%20use%20to%20determine%20potential%20risks.%20Medication%20use%20is%20commonly%20determined%20by%20self-report%2C%20clinician%20records%2C%20and%20electronic%20pharmacy%20data%3B%20different%20data%20sources%20may%20be%20more%20informative%20for%20different%20types%20of%20medication%20and%20resources%20may%20differ%20by%20setting.%20We%20compared%20three%20methods%20to%20determine%20antenatal%20medicine%20use%20%28self-report%2C%20clinician%20records%20and%20electronic%20pharmacy%20dispensing%20records%20%5BEDR%5D%29%20in%20women%20attending%20antenatal%20care%20at%20a%20primary%20care%20facility%20in%20Cape%20Town%2C%20South%20Africa%20in%20a%20setting%20with%20high%20HIV%20prevalence.%20METHODS%3A%20Structured%2C%20interview-administered%20questionnaires%20recorded%20self-reported%20medicine%20use.%20Data%20were%20collected%20from%20clinician%20records%20and%20EDR%20on%20the%20same%20participants.%20We%20determined%20agreement%20between%20these%20data%20sources%20using%20Cohen%26%23039%3Bs%20kappa%20and%2C%20lacking%20a%20gold%20standard%2C%20used%20Latent%20Class%20Analysis%20to%20estimate%20sensitivity%2C%20specificity%20and%20positive%20predictive%20value%20%28PPV%29%20for%20each%20data%20source.%20RESULTS%3A%20Between%2055%25%20and%2089%25%20of%20967%20women%20had%20any%20medicine%20use%20documented%20depending%20on%20the%20data%20source%20%28median%20number%20of%20medicines%5C%2Fparticipant%20%3D%205%20%5BIQR%203-6%5D%29.%20Agreement%20between%20the%20datasets%20was%20poor%20regardless%20of%20class%20except%20for%20antiretroviral%20therapy%20%28ART%3B%20kappa%200.6-0.71%29.%20Overall%2C%20agreement%20was%20better%20between%20the%20EDR%20and%20self-report%20than%20with%20either%20dataset%20and%20the%20clinician%20records.%20Sensitivity%20and%20PPV%20were%20higher%20for%20self-report%20and%20the%20EDR%20and%20were%20similar%20for%20the%20two.%20Self-report%20was%20the%20best%20source%20for%20over-the-counter%2C%20traditional%20and%20complementary%20medicines%3B%20clinician%20records%20for%20vaccines%20and%20supplements%3B%20and%20EDR%20for%20chronic%20medicines.%20CONCLUSIONS%3A%20Medicine%20use%20in%20pregnancy%20was%20common%20and%20no%20single%20data%20source%20included%20all%20the%20medicines%20used.%20ART%20was%20the%20most%20consistently%20reported%20across%20all%20three%20datasets%20but%20otherwise%20agreement%20between%20them%20was%20poor%20and%20dependent%20on%20class.%20Using%20a%20single%20data%20collection%20method%20will%20under-estimate%20medicine%20use%20in%20pregnancy%20and%20the%20choice%20of%20data%20source%20should%20be%20guided%20by%20the%20class%20of%20the%20agents%20being%20investigated.%22%2C%22date%22%3A%22Jun%203%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12884-022-04765-1%22%2C%22ISSN%22%3A%221471-2393%20%28Electronic%29%201471-2393%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A43%3A14Z%22%7D%7D%2C%7B%22key%22%3A%2286LHART4%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davies%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20Mary-Ann%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKassanjee%2C%20Reshma%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRousseau%2C%20Petro%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMorden%2C%20Erna%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJohnson%2C%20Leigh%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa.%20%26lt%3Bi%26gt%3BTropical%20Medicine%20%26amp%3B%20International%20Health%3A%20TM%20%26amp%3B%20IH%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B27%26lt%3B%5C%2Fi%26gt%3B%20%286%29%2C%20S.%20564%26%23x2013%3B573.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.13752%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.13752%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petro%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erna%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wesley%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nei-Yuan%22%2C%22lastName%22%3A%22Hsiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannah%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graeme%22%2C%22lastName%22%3A%22Meintjes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masudah%22%2C%22lastName%22%3A%22Paleker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theuns%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexa%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Dane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamy-Lee%22%2C%22lastName%22%3A%22Bam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariette%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfgang%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Pienaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Naude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neshaad%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayanda%22%2C%22lastName%22%3A%22Mnguni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sue%22%2C%22lastName%22%3A%22Le%20Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%22%2C%22lastName%22%3A%22Murie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hassan%22%2C%22lastName%22%3A%22Mahomed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liezel%22%2C%22lastName%22%3A%22Rossouw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Maughan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jantjie%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ntobeko%20A.%20B.%22%2C%22lastName%22%3A%22Ntusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arifa%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waasila%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheryl%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juanita%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saadiq%22%2C%22lastName%22%3A%22Kariem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melvin%22%2C%22lastName%22%3A%22Moodley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milani%22%2C%22lastName%22%3A%22Wolmarans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Cloete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Western%20Cape%20and%20South%20African%20National%20Departments%20of%20Health%20in%20collaboration%20with%20the%20National%20Institute%20for%20Communicable%20Diseases%20in%20South%20Africa%20Affiliations%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20The%20objective%20was%20to%20compare%20COVID-19%20outcomes%20in%20the%20Omicron-driven%20fourth%20wave%20with%20prior%20waves%20in%20the%20Western%20Cape%2C%20assess%20the%20contribution%20of%20undiagnosed%20prior%20infection%20to%20differences%20in%20outcomes%20in%20a%20context%20of%20high%20seroprevalence%20due%20to%20prior%20infection%20and%20determine%20whether%20protection%20against%20severe%20disease%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%20was%20maintained.%5CnMETHODS%3A%20In%20this%20cohort%20study%2C%20we%20included%20public%20sector%20patients%20aged%20%5Cu226520%5Cu2009years%20with%20a%20laboratory-confirmed%20COVID-19%20diagnosis%20between%2014%20November%20and%2011%20December%202021%20%28wave%20four%29%20and%20equivalent%20prior%20wave%20periods.%20We%20compared%20the%20risk%20between%20waves%20of%20the%20following%20outcomes%20using%20Cox%20regression%3A%20death%2C%20severe%20hospitalisation%20or%20death%20and%20any%20hospitalisation%20or%20death%20%28all%20%5Cu226414%5Cu2009days%20after%20diagnosis%29%20adjusted%20for%20age%2C%20sex%2C%20comorbidities%2C%20geography%2C%20vaccination%20and%20prior%20infection.%5CnRESULTS%3A%20We%20included%205144%20patients%20from%20wave%20four%20and%2011%2C609%20from%20prior%20waves.%20The%20risk%20of%20all%20outcomes%20was%20lower%20in%20wave%20four%20compared%20to%20the%20Delta-driven%20wave%20three%20%28adjusted%20hazard%20ratio%20%28aHR%29%20%5B95%25%20confidence%20interval%20%28CI%29%5D%20for%20death%200.27%20%5B0.19%3B%200.38%5D.%20Risk%20reduction%20was%20lower%20when%20adjusting%20for%20vaccination%20and%20prior%20diagnosed%20infection%20%28aHR%3A%200.41%2C%2095%25%20CI%3A%200.29%3B%200.59%29%20and%20reduced%20further%20when%20accounting%20for%20unascertained%20prior%20infections%20%28aHR%3A%200.72%29.%20Vaccine%20protection%20was%20maintained%20in%20wave%20four%20%28aHR%20for%20outcome%20of%20death%3A%200.24%3B%2095%25%20CI%3A%200.10%3B%200.58%29.%5CnCONCLUSIONS%3A%20In%20the%20Omicron-driven%20wave%2C%20severe%20COVID-19%20outcomes%20were%20reduced%20mostly%20due%20to%20protection%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%2C%20but%20intrinsically%20reduced%20virulence%20may%20account%20for%20a%20modest%20reduction%20in%20risk%20of%20severe%20hospitalisation%20or%20death%20compared%20to%20the%20Delta-driven%20wave.%22%2C%22date%22%3A%222022-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Ftmi.13752%22%2C%22ISSN%22%3A%221365-3156%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222025-03-17T16%3A19%3A46Z%22%7D%7D%2C%7B%22key%22%3A%222TEJ3SEC%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zurcher%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BZurcher%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRiou%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMorrow%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBallif%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKoch%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Estimating%20Tuberculosis%20Transmission%20Risks%20in%20a%20Primary%20Care%20Clinic%20in%20South%20Africa%3A%20Modeling%20of%20Environmental%20and%20Clinical%20Data.%20%26lt%3Bi%26gt%3BJ%20Infect%20Dis%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B225%26lt%3B%5C%2Fi%26gt%3B%20%289%29%2C%20S.%201642%26%23x2013%3B1652.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab534%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab534%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Estimating%20Tuberculosis%20Transmission%20Risks%20in%20a%20Primary%20Care%20Clinic%20in%20South%20Africa%3A%20Modeling%20of%20Environmental%20and%20Clinical%20Data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Koch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bertschinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20F.%22%2C%22lastName%22%3A%22Warner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Middelkoop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Congregate%20settings%2C%20such%20as%20healthcare%20clinics%2C%20may%20play%20an%20essential%20role%20in%20Mycobacterium%20tuberculosis%20%28Mtb%29%20transmission.%20Using%20patient%20and%20environmental%20data%2C%20we%20studied%20transmission%20at%20a%20primary%20care%20clinic%20in%20South%20Africa.%20METHODS%3A%20We%20collected%20patient%20movements%2C%20cough%20frequency%2C%20and%20clinical%20data%2C%20and%20measured%20indoor%20carbon%20dioxide%20%28CO2%29%20levels%2C%20relative%20humidity%2C%20and%20Mtb%20genomes%20in%20the%20air.%20We%20used%20negative%20binomial%20regression%20model%20to%20investigate%20associations.%20RESULTS%3A%20We%20analyzed%20978%20unique%20patients%20who%20contributed%2014%20795%20data%20points.%20The%20median%20patient%20age%20was%2033%20%28interquartile%20range%20%5BIQR%5D%2C%2026-41%29%20years%2C%20and%20757%20%2877.4%25%29%20were%20female.%20Overall%2C%20median%20CO2%20levels%20were%20564%20%28IQR%20495-646%29%20parts%20per%20million%20and%20were%20highest%20in%20the%20morning.%20Median%20number%20of%20coughs%20per%20day%20was%20466%20%28IQR%2C%20368-503%29%2C%20and%20overall%20median%20Mtb%20DNA%20copies%5C%2FmuL%5C%2Fday%20was%204.2%20%28IQR%2C%201.2-9.5%29.%20We%20found%20an%20increased%20presence%20of%20Mtb%20DNA%20in%20the%20air%20of%2032%25%20%2895%25%20credible%20interval%2C%207%25-63%25%29%20per%20100%20additional%20young%20adults%20%28aged%2015-29%20years%29%20and%201%25%20%280-2%25%29%20more%20Mtb%20DNA%20per%2010%25%20increase%20of%20relative%20humidity.%20Estimated%20cumulative%20transmission%20risks%20for%20patients%20attending%20the%20clinic%20monthly%20for%20at%20least%201%20hour%20range%20between%209%25%20and%2029%25.%20CONCLUSIONS%3A%20We%20identified%20young%20adults%20and%20relative%20humidity%20as%20potentially%20important%20factors%20for%20transmission%20risks%20in%20healthcare%20clinics.%20Our%20approach%20should%20be%20used%20to%20detect%20transmission%20and%20evaluate%20infection%20control%20interventions.%22%2C%22date%22%3A%22May%204%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiab534%22%2C%22ISSN%22%3A%221537-6613%20%28Electronic%29%200022-1899%20%28Print%29%200022-1899%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A11%3A00Z%22%7D%7D%2C%7B%22key%22%3A%228NTDZHC5%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussey%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHussey%2C%20H.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20M.%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHeekes%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BWilliamson%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BValley-Omar%2C%20Z.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis.%20%26lt%3Bi%26gt%3BInt%20J%20Infect%20Dis%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B118%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20150%26%23x2013%3B154.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.02.051%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20clinical%20severity%20of%20the%20Omicron%20variant%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20using%20the%20diagnostic%20PCR%20proxy%20marker%20of%20RdRp%20target%20delay%20to%20distinguish%20between%20Omicron%20and%20Delta%20infections%20-%20a%20survival%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Williamson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Valley-Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Hardie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Korsman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Doolabh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Maponga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Iranzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Y.%22%2C%22lastName%22%3A%22Hsiao%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20At%20present%2C%20it%20is%20unclear%20whether%20the%20extent%20of%20reduced%20risk%20of%20severe%20disease%20seen%20with%20SARS-Cov-2%20Omicron%20variant%20infection%20is%20caused%20by%20a%20decrease%20in%20variant%20virulence%20or%20by%20higher%20levels%20of%20population%20immunity.%20METHODS%3A%20RdRp%20target%20delay%20%28RTD%29%20in%20the%20Seegene%20Allplex%28TM%29%202019-nCoV%20PCR%20assay%20is%20a%20proxy%20marker%20for%20the%20Delta%20variant.%20The%20absence%20of%20this%20proxy%20marker%20in%20the%20transition%20period%20was%20used%20to%20identify%20suspected%20Omicron%20infections.%20Cox%20regression%20was%20performed%20for%20the%20outcome%20of%20hospital%20admission%20in%20those%20who%20tested%20positive%20for%20SARS-CoV-2%20on%20the%20Seegene%20Allplex%28TM%29%20assay%20from%20November%201%20to%20December%2014%2C%202021%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%2C%20in%20the%20public%20sector.%20Adjustments%20were%20made%20for%20vaccination%20status%20and%20prior%20diagnosis%20of%20infection.%20RESULTS%3A%20A%20total%20of%20150%20cases%20with%20RTD%20and%201486%20cases%20without%20RTD%20were%20included.%20Cases%20without%20RTD%20had%20a%20lower%20hazard%20of%20admission%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%2C%200.56%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.34-0.91%29.%20Complete%20vaccination%20was%20protective%20against%20admission%2C%20with%20an%20aHR%20of%200.45%20%2895%25%20CI%2C%200.26-0.77%29.%20CONCLUSION%3A%20Omicron%20has%20resulted%20in%20a%20lower%20risk%20of%20hospital%20admission%20compared%20with%20contemporaneous%20Delta%20infection%2C%20when%20using%20the%20proxy%20marker%20of%20RTD.%20Under-ascertainment%20of%20reinfections%20with%20an%20immune%20escape%20variant%20remains%20a%20challenge%20to%20accurately%20assessing%20variant%20virulence.%22%2C%22date%22%3A%22May%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.02.051%22%2C%22ISSN%22%3A%221878-3511%20%28Electronic%29%201201-9712%20%28Print%29%201201-9712%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22A8Q9SL7J%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Muchengeti%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuchengeti%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBartels%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BOlago%2C%20V.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDhokotera%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChen%2C%20W.%20C.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cohort%20profile%3A%20the%20South%20African%20HIV%20Cancer%20Match%20%28SAM%29%20Study%2C%20a%20national%20population-based%20cohort.%20%26lt%3Bi%26gt%3BBMJ%20Open%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%20%284%29%2C%20S.%20e053460.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-053460%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2021-053460%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cohort%20profile%3A%20the%20South%20African%20HIV%20Cancer%20Match%20%28SAM%29%20Study%2C%20a%20national%20population-based%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Muchengeti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Bartels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Olago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Spoerri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Butikofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Ruffieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20South%20African%20HIV%20Cancer%20Match%20%28SAM%29%20Study%20is%20a%20national%20cohort%20of%20people%20living%20with%20HIV%20%28PLWH%29.%20It%20was%20created%20using%20probabilistic%20record%20linkages%20of%20routine%20laboratory%20records%20of%20PLWH%20retrieved%20by%20National%20Health%20Laboratory%20Services%20%28NHLS%29%20and%20cancer%20data%20from%20the%20National%20Cancer%20Registry.%20The%20SAM%20Study%20aims%20to%20assess%20the%20spectrum%20and%20risk%20of%20cancer%20in%20PLWH%20in%20the%20context%20of%20the%20evolving%20South%20African%20HIV%20epidemic.%20The%20SAM%20Study%26%23039%3Bs%20overarching%20goal%20is%20to%20inform%20cancer%20prevention%20and%20control%20programmes%20in%20PLWH%20in%20the%20era%20of%20antiretroviral%20treatment%20in%20South%20Africa.%20PARTICIPANTS%3A%20PLWH%20%28both%20adults%20and%20children%29%20who%20accessed%20HIV%20care%20in%20public%20sector%20facilities%20and%20had%20HIV%20diagnostic%20or%20monitoring%20laboratory%20tests%20from%20NHLS.%20FINDINGS%20TO%20DATE%3A%20The%20SAM%20cohort%20currently%20includes%205%20248%20648%20PLWH%20for%20the%20period%202004%20to%202014%3B%2069%25%20of%20these%20are%20women.%20The%20median%20age%20at%20cohort%20entry%20was%2033.0%20years%20%28IQR%3A%2026.2-40.9%29.%20The%20overall%20cancer%20incidence%20in%20males%20and%20females%20was%20235.9%20%2895%25%20CI%3A%20231.5%20to%20240.5%29%20and%20183.7%20%28181.2-186.2%29%20per%20100%20000%20person-years%2C%20respectively.Using%20data%20from%20the%20SAM%20Study%2C%20we%20examined%20national%20cancer%20incidence%20in%20PLWH%20and%20the%20association%20of%20different%20cancers%20with%20immunodeficiency.%20Cancers%20with%20the%20highest%20incidence%20rates%20were%20Kaposi%20sarcoma%2C%20cervix%2C%20breast%2C%20non-Hodgkin%26%23039%3Bs%20lymphoma%20and%20eye%20cancer.%20FUTURE%20PLANS%3A%20The%20SAM%20Study%20is%20a%20unique%2C%20evolving%20resource%20for%20research%20and%20surveillance%20of%20malignancies%20in%20PLWH.%20The%20SAM%20Study%20will%20be%20regularly%20updated.%20We%20plan%20to%20enrich%20the%20SAM%20Study%20through%20record%20linkages%20with%20other%20laboratory%20data%20within%20the%20NHLS%20%28eg%2C%20tuberculosis%2C%20diabetes%20and%20lipid%20profile%20data%29%2C%20mortality%20data%20and%20socioeconomic%20data%20to%20facilitate%20comprehensive%20epidemiological%20research%20of%20comorbidities%20among%20PLWH.%22%2C%22date%22%3A%22Apr%2011%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2021-053460%22%2C%22ISSN%22%3A%222044-6055%20%28Electronic%29%202044-6055%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22FVHY6C8N%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davies%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJohnson%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSawry%2C%20S.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChimbetete%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEley%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Effect%20of%20antiretroviral%20therapy%20care%20interruptions%20on%20mortality%20in%20children%20living%20with%20HIV.%20%26lt%3Bi%26gt%3BAIDS%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B36%26lt%3B%5C%2Fi%26gt%3B%20%285%29%2C%20S.%20729%26%23x2013%3B737.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003194%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003194%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20antiretroviral%20therapy%20care%20interruptions%20on%20mortality%20in%20children%20living%20with%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Sawry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20G.%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ehmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Rabie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Phiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malisita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Osler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Newton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20characteristics%20and%20outcomes%20of%20HIV-infected%20children%20that%20have%20care%20interruptions%2C%20during%20which%20the%20child%26%23039%3Bs%20health%20status%20and%20use%20of%20medication%20is%20unknown.%20DESIGN%3A%20We%20included%20data%20on%20children%20initiating%20ART%20between%202004%20and%202016%20at%20less%20than%2016%20years%20old%20at%2016%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20Southern%20Africa%20cohorts.%20Children%20were%20classified%20as%20loss%20to%20follow%20up%20%28LTFU%29%20if%20they%20had%20not%20attended%20clinic%20for%20more%20than%20180%20days.%20Children%20had%20a%20care%20interruption%20if%20they%20were%20classified%20as%20LTFU%2C%20and%20subsequently%20returned%20to%20care.%20Children%20who%20died%20within%20180%20days%20of%20ART%20start%20were%20excluded.%20METHODS%3A%20The%20main%20outcome%20was%20all%20cause%20mortality.%20Two%20exposed%20groups%20were%20considered%3A%20those%20with%20a%20first%20care%20interruption%20within%20the%20first%206%20months%20on%20ART%2C%20and%20those%20with%20a%20first%20care%20interruption%20after%206%20months%20on%20ART.%20Adjusted%20hazard%20ratios%20were%20determined%20using%20a%20Cox%20regression%20model.%20RESULTS%3A%20Among%2053%20674%20children%20included%2C%2023%20437%20%2844%25%29%20had%20a%20care%20interruption%2C%20of%20which%2010%20629%20%2820%25%29%20had%20a%20first%20care%20interruption%20within%206%20months%20on%20ART%20and%2012%20808%20%2824%25%29%20had%20a%20first%20care%20interruption%20after%206%20months%20on%20ART.%20Increased%20mortality%20was%20associated%20with%20a%20care%20interruption%20within%206%20months%20on%20ART%20%5Badjusted%20hazard%20ratio%20%28AHR%29%20%3D%201.52%2C%2095%25%20CI%201.12-2.04%5D%20but%20not%20with%20a%20care%20interruption%20after%206%20months%20on%20ART%20%28AHR%20%3D%201.05%2C%2095%25%20CI%200.77-1.44%29.%20CONCLUSION%3A%20The%20findings%20suggest%20that%20strengthening%20retention%20of%20children%20in%20care%20in%20the%20early%20period%20after%20ART%20initiation%20is%20critical%20to%20improving%20paediatric%20ART%20outcomes.%22%2C%22date%22%3A%22Apr%201%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003194%22%2C%22ISSN%22%3A%221473-5571%20%28Electronic%29%200269-9370%20%28Print%29%200269-9370%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22UGGK9LMX%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Staub%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BStaub%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BPanczak%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMatthes%2C%20K.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BFloris%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBerlin%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain.%20%26lt%3Bi%26gt%3BAnn%20Intern%20Med%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B175%26lt%3B%5C%2Fi%26gt%3B%20%284%29%2C%20S.%20523%26%23x2013%3B532.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3824%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Historically%20High%20Excess%20Mortality%20During%20the%20COVID-19%20Pandemic%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Staub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Panczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20L.%22%2C%22lastName%22%3A%22Matthes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Floris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Berlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Junker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Weitkunat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20E.%22%2C%22lastName%22%3A%22Mamelund%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Zwahlen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Riou%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Excess%20mortality%20quantifies%20the%20overall%20mortality%20impact%20of%20a%20pandemic.%20Mortality%20data%20have%20been%20accessible%20for%20many%20countries%20in%20recent%20decades%2C%20but%20few%20continuous%20data%20have%20been%20available%20for%20longer%20periods.%20OBJECTIVE%3A%20To%20assess%20the%20historical%20dimension%20of%20the%20COVID-19%20pandemic%20in%202020%20for%203%20countries%20with%20reliable%20death%20count%20data%20over%20an%20uninterrupted%20span%20of%20more%20than%20100%20years.%20DESIGN%3A%20Observational%20study.%20SETTING%3A%20Switzerland%2C%20Sweden%2C%20and%20Spain%2C%20which%20were%20militarily%20neutral%20and%20not%20involved%20in%20combat%20during%20either%20world%20war%20and%20have%20not%20been%20affected%20by%20significant%20changes%20in%20their%20territory%20since%20the%20end%20of%20the%2019th%20century.%20PARTICIPANTS%3A%20Complete%20populations%20of%20these%203%20countries.%20MEASUREMENTS%3A%20Continuous%20series%20of%20recorded%20deaths%20%28from%20all%20causes%29%20by%20month%20from%20the%20earliest%20available%20year%20%281877%20for%20Switzerland%2C%201851%20for%20Sweden%2C%20and%201908%20for%20Spain%29%20were%20jointly%20modeled%20with%20annual%20age%20group-specific%20death%20and%20total%20population%20counts%20using%20negative%20binomial%20and%20multinomial%20models%2C%20which%20accounted%20for%20temporal%20trends%20and%20seasonal%20variability%20of%20prepandemic%20years.%20The%20aim%20was%20to%20estimate%20the%20expected%20number%20of%20deaths%20in%20a%20pandemic%20year%20for%20a%20nonpandemic%20scenario%20and%20the%20difference%20in%20observed%20and%20expected%20deaths%20aggregated%20over%20the%20year.%20RESULTS%3A%20In%202020%2C%20the%20number%20of%20excess%20deaths%20recorded%20per%20100%20000%20persons%20was%20100%20%2895%25%20credible%20interval%20%5BCrI%5D%2C%2060%20to%20135%29%20for%20Switzerland%2C%2075%20%28CrI%2C%2040%20to%20105%29%20for%20Sweden%2C%20and%20155%20%28CrI%2C%20110%20to%20195%29%20for%20Spain.%20In%201918%2C%20excess%20mortality%20was%206%20to%207%20times%20higher.%20In%20all%203%20countries%2C%20the%20peaks%20of%20monthly%20excess%20mortality%20in%202020%20were%20greater%20than%20most%20monthly%20excess%20mortality%20since%201918%2C%20including%20many%20peaks%20due%20to%20seasonal%20influenza%20and%20heat%20waves%20during%20that%20period.%20LIMITATION%3A%20Historical%20vital%20statistics%20might%20be%20affected%20by%20minor%20completeness%20issues%20before%20the%20beginning%20of%20the%2020th%20century.%20CONCLUSION%3A%20In%202020%2C%20the%20COVID-19%20pandemic%20led%20to%20the%20second-largest%20infection-related%20mortality%20disaster%20in%20Switzerland%2C%20Sweden%2C%20and%20Spain%20since%20the%20beginning%20of%20the%2020th%20century.%20PRIMARY%20FUNDING%20SOURCE%3A%20Foundation%20for%20Research%20in%20Science%20and%20the%20Humanities%20at%20the%20University%20of%20Zurich%2C%20Swiss%20National%20Science%20Foundation%2C%20and%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-3824%22%2C%22ISSN%22%3A%221539-3704%20%28Electronic%29%200003-4819%20%28Print%29%200003-4819%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A46%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22V86ICMTD%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAntimycobacterial%20Susceptibility%20Testing%2C%20Group%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment.%20%26lt%3Bi%26gt%3BEur%20Respir%20J%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B59%26lt%3B%5C%2Fi%26gt%3B%20%284%29%2C%20S.%202200166.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Group%22%2C%22lastName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%7D%5D%2C%22abstractNote%22%3A%22Inappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%5CnApproximately%2085%20000%20deaths%20globally%20in%202019%20were%20due%20to%20drug-resistant%20tuberculosis%20%28TB%29%2C%20which%20corresponds%20to%207%25%20of%20global%20deaths%20attributable%20to%20bacterial%20antimicrobial%20resistance%20%5B1%5D.%20Yet%20concerns%20have%20been%20mounting%20that%20drug-resistant%20TB%20was%20being%20underestimated%20because%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-TB%20agents%20had%20not%20kept%20up%20with%20those%20used%20for%20other%20major%20bacterial%20pathogens%20%5B2-9%5D.%20Here%2C%20we%20outline%20the%20recent%2C%20evidence-based%20initiatives%20spearheaded%20by%20the%20World%20Health%20Organization%20%28WHO%29%20and%20others%20to%20update%20breakpoints%20%28traditionally%20referred%20to%20as%20critical%20concentrations%20%28CCs%29%29%20that%20are%20used%20for%20phenotypic%20antimicrobial%20susceptibility%20testing%20%28AST%29%2C%20also%20called%20drug%20susceptibility%20testing%20in%20the%20TB%20literature.%5Cneng%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%221399-3003%20%28Electronic%29%200903-1936%20%28Print%29%200903-1936%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A32%3A48Z%22%7D%7D%2C%7B%22key%22%3A%227LE2GH88%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Justice%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJustice%2C%20A.%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BGoetz%2C%20M.%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BStewart%2C%20C.%20N.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHogan%2C%20B.%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHumes%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.%20%26lt%3Bi%26gt%3BLancet%20HIV%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B9%26lt%3B%5C%2Fi%26gt%3B%20%284%29%2C%20S.%20e269%26%23x2013%3Be280.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Goetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20N.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Rajasuriar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22Late%20presentation%20for%20care%20is%20a%20major%20impediment%20to%20the%20prevention%20and%20effective%20treatment%20of%20HIV%20infection.%20Older%20individuals%20are%20at%20increased%20risk%20of%20late%20presentation%2C%20represent%20a%20growing%20proportion%20of%20people%20with%20late%20presentation%2C%20and%20might%20require%20interventions%20tailored%20to%20their%20age%20group.%20We%20provide%20a%20summary%20of%20the%20literature%20published%20globally%20between%202016-21%20%28reporting%20data%20from%201984-2018%29%20and%20quantify%20the%20association%20of%20age%20with%20delayed%20presentation.%20Using%20the%20most%20common%20definitions%20of%20late%20presentation%20and%20older%20age%20from%20these%20earlier%20studies%2C%20we%20update%20this%20work%20with%20data%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%2C%20focusing%20on%20data%20from%202000-19%2C%20encompassing%20four%20continents.%20Finally%2C%20we%20consider%20how%20late%20presentation%20among%20older%20individuals%20might%20be%20more%20effectively%20addressed%20as%20electronic%20medical%20records%20become%20widely%20adopted.%22%2C%22date%22%3A%22Apr%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2822%2900003-0%22%2C%22ISSN%22%3A%222352-3018%20%28Electronic%29%202405-4704%20%28Print%29%202352-3018%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A18%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22D975QH29%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Riebensahm%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRiebensahm%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChitundu%2C%20H.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuula%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChihota%2C%20B.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSinkala%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Screening%20for%20hepatocellular%20carcinoma%20among%20adults%20with%20HIV%5C%2FHBV%20co-infection%20in%20Zambia%3A%20a%20pilot%20study.%20%26lt%3Bi%26gt%3BInt%20J%20Infect%20Dis%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B116%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%20391%26%23x2013%3B396.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2021.12.338%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2021.12.338%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Screening%20for%20hepatocellular%20carcinoma%20among%20adults%20with%20HIV%5C%2FHBV%20co-infection%20in%20Zambia%3A%20a%20pilot%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Chitundu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sinkala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Sunkutu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20F.%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Berzigotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20E.%20A.%20Southern%20Africa%22%2C%22lastName%22%3A%22Ie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20AIMS%3A%20Chronic%20hepatitis%20B%20virus%20%28HBV%29%20infection%20is%20the%20main%20cause%20of%20hepatocellular%20carcinoma%20%28HCC%29%20in%20sub-Saharan%20Africa%20%28SSA%29.%20An%20HCC%20screening%20initiative%20was%20piloted%20in%20an%20established%20cohort%20of%20individuals%20co-infected%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20and%20HBV%20on%20antiretroviral%20therapy%20%28ART%29%20at%20two%20outpatient%20clinics%20in%20Lusaka%2C%20Zambia.%20METHODS%3A%20All%20patients%20underwent%20abdominal%20ultrasound%20%28AUS%29%20and%20transient%20elastography.%20RESULTS%3A%20Among%20279%20patients%20co-infected%20with%20HIV%5C%2FHBV%2C%20165%20%2859.1%25%29%20were%20men%2C%20median%20age%20was%2034%20years%20%5Binterquartile%20range%20%28IQR%29%2028-39%20years%5D%20and%20median%20CD4%20count%20was%20246%20cells%5C%2FmicroL%20%28IQR%20112-355%20cells%5C%2FmicroL%29%20at%20ART%20initiation.%20While%20102%20%2855.7%25%29%20individuals%20had%20elevated%20transaminases%2C%20114%20%2859.7%25%29%20had%20HBV%20levels%20%26gt%3B2000%20IU%5C%2FmL%20and%2059%20%2824.6%25%29%20had%20significant%20fibrosis.%20At%20their%20first%20AUS%20measurement%2C%2075%20%2826.9%25%29%20participants%20had%20hepatomegaly%20and%2069%20%2824.7%25%29%20had%20periportal%20fibrosis.%20Five%20patients%20had%20a%20liver%20lesion%20%26gt%3B1%20cm%2C%20an%20indication%20for%20confirmatory%20imaging.%20CONCLUSIONS%3A%20In%20one%20of%20the%20first%20HCC%20screening%20initiatives%20in%20SSA%2C%202%25%20of%20patients%20co-infected%20with%20HIV%5C%2FHBV%20had%20significant%20liver%20lesions%2C%20and%20one-quarter%20had%20findings%20suggestive%20of%20schistosomiasis-induced%20liver%20damage.%22%2C%22date%22%3A%22Mar%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2021.12.338%22%2C%22ISSN%22%3A%221878-3511%20%28Electronic%29%201201-9712%20%28Print%29%201201-9712%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22JSS8DS84%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A14%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCollaborative%20Initiative%20for%20Paediatric%2C%20H.%20I.%20V.%20Education%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BResearch%20Global%20Cohort%2C%20Collaboration%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJesson%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCrichton%2C%20S.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BQuartagno%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%283%29%2C%20S.%20e25871.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25871%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20and%20CD4%20patterns%20of%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20worldwide%2C%20a%20CIPHER%20cohort%20collaboration%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20I.%20V.%20Education%22%2C%22lastName%22%3A%22Collaborative%20Initiative%20for%20Paediatric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Collaboration%22%2C%22lastName%22%3A%22Research%20Global%20Cohort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Crichton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Quartagno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20J.%22%2C%22lastName%22%3A%22Abrams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chokephaibulkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Coeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Ake-Assi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ben-Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Van%20Dyke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Judd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mofenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vicari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Seage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20G.%22%2C%22lastName%22%3A%22Bekker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Essajee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Gibb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Penazzato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20J.%22%2C%22lastName%22%3A%22Collins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Powis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Matshaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Thahane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyasulu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Lukhele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Mwita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kekitiinwa-Rukyalekere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wanless%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Goetghebuer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Thorne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Warszawski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Galli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20M.%20C.%22%2C%22lastName%22%3A%22van%20Rossum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Giaquinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Marczynska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Marques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Prata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Ene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Okhonskaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Frick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Naver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kahlert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Volokha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chappell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Marcelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Ogalo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20A.%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bolton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Tweya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sylla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22D%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Renner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Abzug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Oleske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Purswani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Teasdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Nuwagaba-Biribonwoha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Goodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leroy%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescents%20living%20with%20HIV%20are%20subject%20to%20multiple%20co-morbidities%2C%20including%20growth%20retardation%20and%20immunodeficiency.%20We%20describe%20growth%20and%20CD4%20evolution%20during%20adolescence%20using%20data%20from%20the%20Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20global%20project.%20METHODS%3A%20Data%20were%20collected%20between%201994%20and%202015%20from%2011%20CIPHER%20networks%20worldwide.%20Adolescents%20with%20perinatally%20acquired%20HIV%20infection%20%28APH%29%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20before%20age%2010%20years%2C%20with%20at%20least%20one%20height%20or%20CD4%20count%20measurement%20while%20aged%2010-17%20years%2C%20were%20included.%20Growth%20was%20measured%20using%20height-for-age%20Z-scores%20%28HAZ%2C%20stunting%20if%20%26lt%3B-2%20SD%2C%20WHO%20growth%20charts%29.%20Linear%20mixed-effects%20models%20were%20used%20to%20study%20the%20evolution%20of%20each%20outcome%20between%20ages%2010%20and%2017.%20For%20growth%2C%20sex-specific%20models%20with%20fractional%20polynomials%20were%20used%20to%20model%20non-linear%20relationships%20for%20age%20at%20ART%20initiation%2C%20HAZ%20at%20age%2010%20and%20time%2C%20defined%20as%20current%20age%20from%2010%20to%2017%20years%20of%20age.%20RESULTS%3A%20A%20total%20of%2020%2C939%20and%2019%2C557%20APH%20were%20included%20for%20the%20growth%20and%20CD4%20analyses%2C%20respectively.%20Half%20were%20females%2C%20two-thirds%20lived%20in%20East%20and%20Southern%20Africa%2C%20and%20median%20age%20at%20ART%20initiation%20ranged%20from%20%26lt%3B3%20years%20in%20North%20America%20and%20Europe%20to%20%26gt%3B7%20years%20in%20sub-Saharan%20African%20regions.%20At%20age%2010%2C%20stunting%20ranged%20from%206%25%20in%20North%20America%20and%20Europe%20to%2039%25%20in%20the%20Asia-Pacific%3B%2019%25%20overall%20had%20CD4%20counts%20%26lt%3B500%20cells%5C%2Fmm%283%29%20.%20Across%20adolescence%2C%20higher%20HAZ%20was%20observed%20in%20females%20and%20among%20those%20in%20high-income%20countries.%20APH%20with%20stunting%20at%20age%2010%20and%20those%20with%20late%20ART%20initiation%20%28after%20age%205%29%20had%20the%20largest%20HAZ%20gains%20during%20adolescence%2C%20but%20these%20gains%20were%20insufficient%20to%20catch-up%20with%20non-stunted%2C%20early%20ART-treated%20adolescents.%20From%20age%2010%20to%2016%20years%2C%20mean%20CD4%20counts%20declined%20from%20768%20to%20607%20cells%5C%2Fmm%283%29%20.%20This%20decline%20was%20observed%20across%20all%20regions%2C%20in%20males%20and%20females.%20CONCLUSIONS%3A%20Growth%20patterns%20during%20adolescence%20differed%20substantially%20by%20sex%20and%20region%2C%20while%20CD4%20patterns%20were%20similar%2C%20with%20an%20observed%20CD4%20decline%20that%20needs%20further%20investigation.%20Early%20diagnosis%20and%20timely%20initiation%20of%20treatment%20in%20early%20childhood%20to%20prevent%20growth%20retardation%20and%20immunodeficiency%20are%20critical%20to%20improving%20APH%20growth%20and%20CD4%20outcomes%20by%20the%20time%20they%20reach%20adulthood.%22%2C%22date%22%3A%22Mar%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25871%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222025-03-17T12%3A44%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22EWLGRDXE%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Taghavi%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTaghavi%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMandiriri%2C%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BShamu%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRohner%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BButikofer%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cervical%20Cancer%20Screening%20Cascade%20for%20women%20living%20with%20HIV%3A%20a%20cohort%20study%20from%20Zimbabwe.%20%26lt%3Bi%26gt%3BPLOS%20Glob%20Public%20Health%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B2%26lt%3B%5C%2Fi%26gt%3B%20%282%29%2C%20S.%20e0000156.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000156%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000156%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20Cancer%20Screening%20Cascade%20for%20women%20living%20with%20HIV%3A%20a%20cohort%20study%20from%20Zimbabwe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Butikofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Asangbeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Magure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pascoe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Sadeep%22%2C%22lastName%22%3A%22Shrestha%22%7D%5D%2C%22abstractNote%22%3A%22Countries%20with%20high%20HIV%20prevalence%2C%20predominantly%20in%20sub-Sahahran%20Africa%2C%20have%20the%20highest%20cervical%20cancer%20rates%20globally.%20HIV%20care%20cascades%20successfully%20facilitated%20the%20scale-up%20of%20antiretroviral%20therapy.%20A%20cascade%20approach%20could%20similarly%20succeed%20to%20scale-up%20cervical%20cancer%20screening%2C%20supporting%20WHO%26%23039%3Bs%20goal%20to%20eliminate%20cervical%20cancer.%20We%20defined%20a%20Cervical%20Cancer%20Screening%20Cascade%20for%20women%20living%20with%20HIV%20%28WLHIV%29%2C%20evaluating%20the%20continuum%20of%20cervical%20cancer%20screening%20integrated%20into%20an%20HIV%20clinic%20in%20Zimbabwe.%20We%20included%20WLHIV%20aged%20%26gt%3B%5C%2F%3D18%20years%20enrolled%20at%20Newlands%20Clinic%20in%20Harare%20from%20June%202012-2017%20and%20followed%20them%20until%20June%202018.%20We%20used%20a%20cascade%20approach%20to%20evaluate%20the%20full%20continuum%20of%20secondary%20prevention%20from%20screening%20to%20treatment%20of%20pre-cancer%20and%20follow-up.%20We%20report%20percentages%2C%20median%20time%20to%20reach%20cascade%20stages%2C%20and%20cumulative%20incidence%20at%20two%20years%20with%2095%25%20confidence%20intervals%20%28CI%29.%20We%20used%20univariable%20Cox%20proportional%20hazard%20regressions%20to%20calculate%20cause-specific%20hazard%20ratios%20with%2095%25%20CIs%20for%20factors%20associated%20with%20completing%20the%20cascade%20stages.%20We%20included%201624%20WLHIV%20in%20the%20study.%20The%20cumulative%20incidence%20of%20cervical%20screening%20was%2085.4%25%20%2895%25%20CI%2083.5-87.1%29%20at%20two%20years.%20Among%20the%20396%20WLHIV%20who%20received%20screen-positive%20tests%20in%20the%20study%2C%20the%20cumulative%20incidence%20of%20treatment%20after%20a%20positive%20screening%20test%20was%2079.5%25%20%2895%25%20CI%2075.1-83.2%29%20at%20two%20years.%20The%20cumulative%20incidence%20of%20testing%20negative%20at%20re-screening%20after%20treatment%20was%2036.1%25%20%2895%25%20CI%2031.2-40.7%29%20at%20two%20years.%20Using%20a%20cascade%20approach%20to%20evaluate%20the%20full%20continuum%20of%20cervical%20cancer%20screening%2C%20we%20found%20less-than%2080%25%20of%20WLHIV%20received%20treatment%20after%20screen-positive%20tests%20and%20less-than%2040%25%20were%20screen-negative%20at%20follow-up.%20Interventions%20to%20improve%20linkage%20to%20treatment%20for%20screen-positive%20WLHIV%20and%20studies%20to%20understand%20the%20clinical%20significance%20of%20screen-positive%20tests%20at%20follow-up%20among%20WLHIV%20are%20needed.%20These%20gaps%20in%20the%20continuum%20of%20care%20must%20be%20addressed%20in%20order%20to%20prevent%20cervical%20cancer.%22%2C%22date%22%3A%222022-2-2%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pgph.0000156%22%2C%22ISSN%22%3A%222767-3375%20%28Electronic%29%202767-3375%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22Y4K7D96I%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ballif%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBallif%2C%20Marie%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChrist%2C%20Benedikt%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAnderegg%2C%20Nanina%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BChammartin%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMuhairwe%2C%20Josephine%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Tracing%20People%20Living%20With%20Human%20Immunodeficiency%20Virus%20Who%20Are%20Lost%20to%20Follow-up%20at%20Antiretroviral%20Therapy%20Programs%20in%20Southern%20Africa%3A%20A%20Sampling-Based%20Cohort%20Study%20in%206%20Countries.%20%26lt%3Bi%26gt%3BClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B74%26lt%3B%5C%2Fi%26gt%3B%20%282%29%2C%20S.%20171%26%23x2013%3B179.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab428%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab428%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tracing%20People%20Living%20With%20Human%20Immunodeficiency%20Virus%20Who%20Are%20Lost%20to%20Follow-up%20at%20Antiretroviral%20Therapy%20Programs%20in%20Southern%20Africa%3A%20A%20Sampling-Based%20Cohort%20Study%20in%206%20Countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedikt%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanina%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Chammartin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josephine%22%2C%22lastName%22%3A%22Muhairwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Jefferys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Hector%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janneke%22%2C%22lastName%22%3A%22van%20Dijk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22van%20Lettow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%20J.%22%2C%22lastName%22%3A%22Phiri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorina%22%2C%22lastName%22%3A%22Onoya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Attrition%20threatens%20the%20success%20of%20antiretroviral%20therapy%20%28ART%29.%20In%20this%20cohort%20study%2C%20we%20examined%20outcomes%20of%20people%20living%20with%20human%20immunodeficiency%20virus%20%28PLHIV%29%20who%20were%20lost%20to%20follow-up%20%28LTFU%29%20during%202014-2017%20at%20ART%20programs%20in%20Southern%20Africa.%5CnMETHODS%3A%20We%20confirmed%20LTFU%20%28missed%20appointment%20for%20%5Cu226560%20or%20%5Cu226590%20days%2C%20according%20to%20local%20guidelines%29%20by%20checking%20medical%20records%20and%20used%20a%20standardized%20protocol%20to%20trace%20a%20weighted%20random%20sample%20of%20PLHIV%20who%20were%20LTFU%20in%208%20ART%20programs%20in%20Lesotho%2C%20Malawi%2C%20Mozambique%2C%20South%20Africa%2C%20Zambia%2C%20and%20Zimbabwe%2C%202017-2019.%20We%20ascertained%20vital%20status%20and%20identified%20predictors%20of%20mortality%20using%20logistic%20regression%2C%20adjusted%20for%20sex%2C%20age%2C%20time%20on%20ART%2C%20time%20since%20LTFU%2C%20travel%20time%2C%20and%20urban%20or%20rural%20setting.%5CnRESULTS%3A%20Among%203256%20PLHIV%2C%20385%20%2812%25%29%20were%20wrongly%20categorized%20as%20LTFU%20and%20577%20%2817%25%29%20had%20missing%20contact%20details.%20We%20traced%202294%20PLHIV%20%2871%25%29%20by%20phone%20calls%2C%20home%20visits%2C%20or%20both%3A%20768%20%2834%25%20of%202294%29%20were%20alive%20and%20in%20care%2C%20including%20385%20%2817%25%29%20silent%20transfers%20to%20another%20clinic%3B%20528%20%2823%25%29%20were%20alive%20without%20care%20or%20unknown%20care%3B%20252%20%2811%25%29%20had%20died.%20Overall%2C%20the%20status%20of%201323%20%2841%25%20of%203256%29%20PLHIV%20remained%20unknown.%20Mortality%20was%20higher%20in%20men%20than%20women%2C%20higher%20in%20children%20than%20in%20young%20people%20or%20adults%2C%20and%20higher%20in%20PLHIV%20who%20had%20been%20on%20ART%20%26lt%3B1%20year%20or%20LTFU%20%5Cu22651%20year%20and%20those%20living%20farther%20from%20the%20clinic%20or%20in%20rural%20areas.%20Results%20were%20heterogeneous%20across%20sites.%5CnCONCLUSIONS%3A%20Our%20study%20highlights%20the%20urgent%20need%20for%20better%20medical%20record%20systems%20at%20HIV%20clinics%20and%20rapid%20tracing%20of%20PLHIV%20who%20are%20LTFU.%22%2C%22date%22%3A%222022-01-29%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciab428%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-21T14%3A16%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22JEWIU9VH%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dhokotera%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-27%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDhokotera%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BAsangbeh%2C%20S.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBohlius%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSingh%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEgger%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Cervical%20cancer%20in%20women%20living%20in%20South%20Africa%3A%20a%20record%20linkage%20study%20of%20the%20National%20Health%20Laboratory%20Service%20and%20the%20National%20Cancer%20Registry.%20%26lt%3Bi%26gt%3BEcancermedicalscience%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B16%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%201348.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3332%5C%2Fecancer.2022.1348%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3332%5C%2Fecancer.2022.1348%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20in%20women%20living%20in%20South%20Africa%3A%20a%20record%20linkage%20study%20of%20the%20National%20Health%20Laboratory%20Service%20and%20the%20National%20Cancer%20Registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Asangbeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ncayiyana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20M.%22%2C%22lastName%22%3A%22Clifford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Olago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Sengayi-Muchengeti%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%20countries%20with%20high%20HIV%20prevalence%2C%20it%20is%20important%20to%20understand%20the%20cervical%20cancer%20%28CC%29%20patterns%20by%20HIV%20status%20to%20ensure%20targeted%20prevention%20measures.%20We%20aimed%20to%20determine%20the%20factors%20associated%20with%20CC%20compared%20to%20non-infection%20related%20cancer%20in%20women%20living%20in%20South%20Africa.%20METHODS%3A%20This%20was%20a%20cross-sectional%20study%20of%20women%20aged%2015%20years%20and%20older%20diagnosed%20with%20CC%20and%20non-infection%20related%20cancer%20in%20the%20South%20African%20public%20health%20sector%20from%202004%20to%202014.%20The%20National%20Cancer%20Registry%20provided%20data%20on%20cancer%2C%20whilst%20HIV%20status%20was%20determined%20from%20routinely%20collected%20HIV%20related%20data%20from%20the%20National%20Health%20Laboratory%20Service.%20We%20explored%20the%20association%20of%20HIV%20infection%2C%20age%2C%20ethnicity%20and%20calendar%20period%20with%20CC%20compared%20to%20non-infection%20related%20cancer.%20RESULTS%3A%20From%202004%20to%202014%2C%2049%2C599%20women%20were%20diagnosed%20with%20CC%2C%20whilst%2078%2C687%20women%20had%20non-infection%20related%20cancer.%20About%2040%25%20%28n%20%3D%2020%2C063%29%20of%20those%20with%20CC%20and%2028%25%20%28n%20%3D%205%2C667%29%20of%20those%20with%20non-infection%20related%20cancer%20had%20a%20known%20HIV%20status.%20The%20median%20age%20at%20CC%20diagnosis%20was%2044%20years%20%28interquartile%20range%20%28IQR%29%3A%2037-52%29%20and%2054%20years%20%28IQR%3A%2046-64%29%20for%20HIV%20positive%20and%20negative%20women%2C%20respectively%2C%20and%20for%20non-infection%20related%20cancer%2C%2045%20years%20%28IQR%3A%2047-55%29%20and%2056%20years%20%28IQR%3A%2047-66%29%20for%20HIV%20negative%20and%20positive%20women%2C%20respectively.%20Diagnosis%20of%20CC%20was%20associated%20with%20HIV%20positivity%2C%20Black%20ethnicity%2C%20earlier%20calendar%20period%20%282004-2006%29%20and%20the%20ages%2030-49%20years.%20In%20comparison%20with%20Black%20women%2C%20the%20odds%20of%20CC%20were%2044%25%20less%20in%20Coloured%20women%2C%2050%25%20less%20in%20Asian%20women%20and%2051%25%20less%20in%20White%20women.%20CONCLUSIONS%3A%20HIV%20positive%20women%20presented%20a%20decade%20earlier%20with%20CC%20compared%20to%20HIV%20negative%20women.%20A%20large%20proportion%20of%20women%20with%20CC%20were%20unaware%20of%20their%20HIV%20status%20with%20a%20disproportionate%20burden%20of%20CC%20in%20Black%20women.%20We%20recommend%20women%20attending%20CC%20screening%20facilities%20to%20be%20offered%20HIV%20testing%20so%20that%20recommendations%20for%20their%20follow-up%20visits%20are%20given%20according%20to%20their%20HIV%20status.%22%2C%22date%22%3A%222022-01-27%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3332%5C%2Fecancer.2022.1348%22%2C%22ISSN%22%3A%221754-6605%20%28Print%29%201754-6605%20%28Electronic%29%201754-6605%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A10%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22JNYBYHLP%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Davies%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDavies%2C%20M.%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKassanjee%2C%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRosseau%2C%20P.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMorden%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BJohnson%2C%20L.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa.%20%26lt%3Bi%26gt%3BMedRxiv%26lt%3B%5C%2Fi%26gt%3B%2C%20S.%202022.01.12.22269148.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.01.12.22269148%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2022.01.12.22269148%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20laboratory-confirmed%20SARS-CoV-2%20infection%20in%20the%20Omicron-driven%20fourth%20wave%20compared%20with%20previous%20waves%20in%20the%20Western%20Cape%20Province%2C%20South%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rosseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Morden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Y.%22%2C%22lastName%22%3A%22Hsiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Hussey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Meintjes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Paleker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Jacobs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Raubenheimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Heekes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Dane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Bam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Preiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Pienaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mendelson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Naude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Schrueder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Mnguni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20L.%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Murie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Mahomed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Rossouw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Maughan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Boloko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Taljaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Symons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ntusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Parker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Wolter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Jassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Lessells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Arendse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Kariem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moodley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Vallabhjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wolmarans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Cloete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20We%20aimed%20to%20compare%20COVID-19%20outcomes%20in%20the%20Omicron-driven%20fourth%20wave%20with%20prior%20waves%20in%20the%20Western%20Cape%2C%20the%20contribution%20of%20undiagnosed%20prior%20infection%20to%20differences%20in%20outcomes%20in%20a%20context%20of%20high%20seroprevalence%20due%20to%20prior%20infection%2C%20and%20whether%20protection%20against%20severe%20disease%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%20was%20maintained.%20METHODS%3A%20In%20this%20cohort%20study%2C%20we%20included%20public%20sector%20patients%20aged%20%26gt%3B%5C%2F%3D20%20years%20with%20a%20laboratory%20confirmed%20COVID-19%20diagnosis%20between%2014%20November-11%20December%202021%20%28wave%20four%29%20and%20equivalent%20prior%20wave%20periods.%20We%20compared%20the%20risk%20between%20waves%20of%20the%20following%20outcomes%20using%20Cox%20regression%3A%20death%2C%20severe%20hospitalization%20or%20death%20and%20any%20hospitalization%20or%20death%20%28all%20%26lt%3B%5C%2F%3D14%20days%20after%20diagnosis%29%20adjusted%20for%20age%2C%20sex%2C%20comorbidities%2C%20geography%2C%20vaccination%20and%20prior%20infection.%20RESULTS%3A%20We%20included%205%2C144%20patients%20from%20wave%20four%20and%2011%2C609%20from%20prior%20waves.%20Risk%20of%20all%20outcomes%20was%20lower%20in%20wave%20four%20compared%20to%20the%20Delta-driven%20wave%20three%20%28adjusted%20Hazard%20Ratio%20%28aHR%29%20%5B95%25%20confidence%20interval%20%28CI%29%5D%20for%20death%200.27%20%5B0.19%3B%200.38%5D.%20Risk%20reduction%20was%20lower%20when%20adjusting%20for%20vaccination%20and%20prior%20diagnosed%20infection%20%28aHR%3A0.41%2C%2095%25%20CI%3A%200.29%3B%200.59%29%20and%20reduced%20further%20when%20accounting%20for%20unascertained%20prior%20infections%20%28aHR%3A%200.72%29.%20Vaccine%20protection%20was%20maintained%20in%20wave%20four%20%28aHR%20for%20outcome%20of%20death%3A%200.24%3B%2095%25%20CI%3A%200.10%3B%200.58%29.%20CONCLUSIONS%3A%20In%20the%20Omicron-driven%20wave%2C%20severe%20COVID-19%20outcomes%20were%20reduced%20mostly%20due%20to%20protection%20conferred%20by%20prior%20infection%20and%5C%2For%20vaccination%2C%20but%20intrinsically%20reduced%20virulence%20may%20account%20for%20an%20approximately%2025%25%20reduced%20risk%20of%20severe%20hospitalization%20or%20death%20compared%20to%20Delta.%22%2C%22date%22%3A%22Jan%2012%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1101%5C%2F2022.01.12.22269148%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A26%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22B7GLFP6C%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyemba%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNyemba%2C%20D.%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKalk%2C%20E.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BVinikoor%2C%20M.%20J.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMadlala%2C%20H.%20P.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMubiana-Mbewe%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Growth%20patterns%20of%20infants%20with%20in-%20utero%20HIV%20and%20ARV%20exposure%20in%20Cape%20Town%2C%20South%20Africa%20and%20Lusaka%2C%20Zambia.%20%26lt%3Bi%26gt%3BBMC%20Public%20Health%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B22%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%2055.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-12476-z%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-12476-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Growth%20patterns%20of%20infants%20with%20in-%20utero%20HIV%20and%20ARV%20exposure%20in%20Cape%20Town%2C%20South%20Africa%20and%20Lusaka%2C%20Zambia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20C.%22%2C%22lastName%22%3A%22Nyemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kalk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20P.%22%2C%22lastName%22%3A%22Madlala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mubiana-Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mzumara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Slogrove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Myer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Powis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Infants%20born%20HIV-exposed%20yet%20remain%20uninfected%20%28HEU%29%20are%20at%20increased%20risk%20of%20poorer%20growth%20and%20health%20compared%20to%20infants%20born%20HIV-unexposed%20%28HU%29.%20Whether%20maternal%20antiretroviral%20treatment%20%28ART%29%20in%20pregnancy%20ameliorates%20this%20risk%20of%20poorer%20growth%20is%20not%20well%20understood.%20Furthermore%2C%20whether%20risks%20are%20similar%20across%20high%20burden%20HIV%20settings%20has%20not%20been%20extensively%20explored.%20METHODS%3A%20We%20harmonized%20data%20from%20two%20prospective%20observational%20studies%20conducted%20in%20Cape%20Town%2C%20South%20Africa%2C%20and%20Lusaka%2C%20Zambia%2C%20to%20compare%20weight-for-age%20%28WAZ%29%2C%20length-for-age%20%28LAZ%29%20and%20weight-for-length%20%28WLZ%29%20Z-scores%20between%20infants%20who%20were%20HEU%20and%20HU%2C%20converting%20infant%20anthropometric%20measures%20using%20World%20Health%20Organisation%20Growth%20Standards%20adjusted%20for%20age%20and%20sex.%20Linear%20mixed%20effects%20models%20were%20fit%20to%20identify%20risk%20factors%20for%20differences%20in%20anthropometrics%20at%206-10%20weeks%20and%206%20months%20by%20infant%20HIV%20exposures%20status%20and%20by%20timing%20of%20exposure%20to%20maternal%20ART%2C%20either%20from%20conception%20or%20later%20in%20gestation.%20RESULTS%3A%20Overall%20773%20mother-infant%20pairs%20were%20included%20across%20two%20countries%3A%20women%20living%20with%20HIV%20%28WLHIV%29%2C%2051%25%20%28n%20%3D%20395%29%20with%2065%25%20on%20ART%20at%20conception%20and%2035%25%20initiating%20treatment%20in%20pregnancy.%20In%20linear%20mixed%20effects%20models%2C%20WAZ%20and%20WLZ%20at%206-10%20weeks%20were%20lower%20among%20infants%20who%20were%20HEU%20vs%20HU%20%5Bbeta%20%3D%20-%200.29%20%2895%25%20CI%3A%20-%200.46%2C%20-%200.12%29%20and%20%5Bbeta%20%3D%20-%200.42%20%2895%25%20CI%3A%20-%200.68%2C%20-%200.16%29%5D%20respectively%20after%20adjusting%20for%20maternal%20characteristics%20and%20infant%20feeding%20with%20a%20random%20intercept%20for%20country.%20At%206%20months%2C%20LAZ%20was%20lower%20%5Bbeta%20%3D%20-%200.28%20CI%3A%20-%200.50%2C%20-%200.06%29%5D%20among%20infants%20who%20were%20HEU%2C%20adjusting%20for%20the%20same%20variables%2C%20with%20no%20differences%20in%20WAZ%20and%20WLZ.%20Within%20cohort%20evaluations%20identified%20different%20results%20with%20higher%20LAZ%20among%20infants%20who%20were%20HEU%20from%20Zambia%20at%206-10%20weeks%2C%20%5Bbeta%20%3D%20%2B%200.34%20CI%3A%20%2B%200.01%2C%20%2B%200.68%29%5D%20and%20lower%20LAZ%20among%20infants%20who%20were%20HEU%20from%20South%20Africa%20%5Bbeta%20%3D%20-%200.30%20CI%3A%20-%200.59%2C%20-%200.01%29%5D%20at%206%20months%2C%20without%20other%20anthropometric%20differences%20at%20either%20site.%20CONCLUSION%3A%20Infant%20growth%20trajectories%20differed%20by%20country%2C%20highlighting%20the%20importance%20of%20studying%20contextual%20influences%20on%20outcomes%20of%20infants%20who%20were%20HEU.%22%2C%22date%22%3A%22Jan%2010%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-021-12476-z%22%2C%22ISSN%22%3A%221471-2458%20%28Electronic%29%201471-2458%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A45%3A54Z%22%7D%7D%2C%7B%22key%22%3A%226LXEJH9B%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyakato%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BNyakato%2C%20P.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BSchomaker%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BFatti%2C%20G.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BTanser%2C%20F.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEuvrard%2C%20J.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Virologic%20non-suppression%20and%20early%20loss%20to%20follow%20up%20among%20pregnant%20and%20non-pregnant%20adolescents%20aged%2015-19%20years%20initiating%20antiretroviral%20therapy%20in%20South%20Africa%3A%20a%20retrospective%20cohort%20study.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%20e25870.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25870%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25870%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Virologic%20non-suppression%20and%20early%20loss%20to%20follow%20up%20among%20pregnant%20and%20non-pregnant%20adolescents%20aged%2015-19%20years%20initiating%20antiretroviral%20therapy%20in%20South%20Africa%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nyakato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Older%20adolescents%20aged%2015-19%20years%20continue%20to%20have%20high%20rates%20of%20loss%20to%20follow%20up%20%28LTFU%29%2C%20and%20high%20rates%20of%20virologic%20non-suppression%20%28VNS%29%20compared%20to%20younger%20adolescents%20and%20adults.%20Adolescent%20females%20are%20at%20risk%20of%20pregnancy%2C%20which%20puts%20those%20living%20with%20HIV%20at%20a%20dual%20vulnerability.%20Our%20study%20assessed%20the%20factors%20associated%20with%20VNS%20and%20LTFU%20in%20older%20adolescents%20%28including%20pregnant%20females%29%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20in%20South%20Africa.%20METHODS%3A%20We%20included%20adolescents%20aged%2015-19%20years%20initiating%20ART%20between%202004%20and%202019%2C%20with%20%26gt%3B%5C%2F%3D%20one%20viral%20load%20%28VL%29%20measurement%20between%204%20and%2024.5%20months%2C%20and%20%26gt%3B%5C%2F%3D%206%20months%20follow-up%2C%20from%20six%20South%20African%20cohorts%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS-Southern%20Africa%20%28IeDEA-SA%29.%20We%20defined%20VNS%20as%20VL%20%26gt%3B%5C%2F%3D400%20copies%5C%2Fml%20and%20LTFU%20as%20not%20being%20in%20care%20for%20%26gt%3B%5C%2F%3D180%20days%20from%20ART%20start%20and%20not%20known%20as%20transferred%20out%20of%20the%20clinic%20or%20dead%20in%20the%20first%2024%20months%20on%20ART.%20We%20examined%20factors%20associated%20with%20VNS%20and%20LTFU%20using%20Fine%26amp%3BGray%20competing%20risk%20models.%20RESULTS%3A%20We%20included%20a%20total%20of%202733%20adolescents%2C%20415%20%2815.2%25%29%20males%2C%20median%20%28IQR%29%20age%20at%20ART%20start%20of%2018.6%20%2817.3%2C%2019.4%29%20years.%20Among%20females%2C%20585%5C%2F2318%20%2825.2%25%29%20were%20pregnant.%20Over%20the%2024-month%20follow-up%2C%20424%20%2815.5%25%29%20of%20all%20adolescents%20experienced%20VNS%3A%20range%20%2811.1%25%20pregnant%20females%20and%2020.5%25%20males%29.%20Over%20half%20of%20all%20adolescents%20were%20LTFU%20before%20any%20other%20event%20could%20occur.%20The%20hazard%20of%20VNS%20reduced%20with%20increasing%20age%20and%20CD4%20count%20above%20200%20cells%5C%2Fmul%20at%20ART%20initiation%20among%20all%20adolescents%20having%20adjusted%20for%20all%20measured%20patient%20characteristics%20%5Badjusted%20sub-distribution%20hazard%20ratio%20%28aSHR%29%2019%20vs.%2015%20years%3A%200.50%20%2895%25%20CI%3A%200.36%2C%200.68%29%2C%20aSHR%3A%20%26gt%3B500%20vs.%20%26lt%3B%5C%2F%3D200%20cells%5C%2Fmul%3A%200.22%20%2895%25%20CI%3A%200.16%2C%200.31%29%5D.%20The%20effect%20of%20CD4%20count%20persisted%20in%20pregnant%20females.%20Increasing%20age%20and%20CD4%20count%20%26gt%3B200%20cells%5C%2Fmul%20were%20risk%20factors%20for%20LTFU%20among%20all%20adolescents.%20CONCLUSIONS%3A%20Older%20adolescents%20had%20a%20high%20risk%20of%20LTFU%20shortly%20after%20ART%20start%20and%20a%20low%20risk%20of%20VNS%2C%20especially%20those%20initiating%20treatment%20during%20pregnancy.%20Interventions%20addressing%20adherence%20and%20retention%20should%20be%20incorporated%20into%20adolescent-friendly%20services%20to%20prevent%20VNS%20and%20LTFU%20and%20endeavour%20to%20trace%20lost%20adolescents%20as%20soon%20as%20they%20are%20identified.%22%2C%22date%22%3A%22Jan%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25870%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A33%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22ZPLWK36L%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cassidy%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCassidy%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCornell%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRuneyi%2C%20P.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BDutyulwa%2C%20T.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BKilani%2C%20C.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Attrition%20from%20HIV%20care%20among%20youth%20initiating%20ART%20in%20youth-only%20clinics%20compared%20with%20general%20primary%20healthcare%20clinics%20in%20Khayelitsha%2C%20South%20Africa%3A%20a%20matched%20propensity%20score%20analysis.%20%26lt%3Bi%26gt%3BJ%20Int%20AIDS%20Soc%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B25%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%20e25854.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25854%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25854%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Attrition%20from%20HIV%20care%20among%20youth%20initiating%20ART%20in%20youth-only%20clinics%20compared%20with%20general%20primary%20healthcare%20clinics%20in%20Khayelitsha%2C%20South%20Africa%3A%20a%20matched%20propensity%20score%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Cassidy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Runeyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Dutyulwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kilani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20T.%22%2C%22lastName%22%3A%22Duran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Zokufa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22de%20Azevedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Boulle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Youth%20living%20with%20HIV%20%28YLWH%29%20are%20less%20likely%20to%20initiate%20antiretroviral%20therapy%20%28ART%29%20and%20remain%20in%20care%20than%20older%20adults.%20It%20is%20important%20to%20identify%20effective%20strategies%20to%20address%20the%20needs%20of%20this%20growing%20population%20and%20prevent%20attrition%20from%20HIV%20care.%20Since%202008%2C%20two%20clinics%20have%20offered%20youth-targeted%20services%20exclusively%20to%20youth%20aged%2012-25%20in%20Khayelitsha%2C%20a%20high%20HIV-prevalence%2C%20low-income%20area%20in%20South%20Africa.%20We%20compared%20ART%20attrition%20among%20youth%20in%20these%20two%20clinics%20to%20youth%20in%20regular%20clinics%20in%20the%20same%20area.%20METHODS%3A%20We%20conducted%20a%20propensity%20score%20matched%20cohort%20study%20of%20individuals%20aged%2012-25%20years%20initiating%20ART%20at%20eight%20primary%20care%20clinics%20in%20Khayelitsha%20between%201%20January%202008%20and%201%20April%202018.%20We%20compared%20attrition%2C%20defined%20as%20death%20or%20loss%20to%20follow-up%2C%20between%20those%20attending%20two%20youth%20clinics%20and%20those%20attending%20general%20primary%20healthcare%20clinics%2C%20using%20Cox%20proportional%20hazards%20regression.%20Follow-up%20time%20began%20at%20ART%20initiation%20and%20ended%20at%20attrition%2C%20clinic%20transfer%20or%20dataset%20closure.%20We%20conducted%20sub-analyses%20of%20patients%20attending%20adherence%20clubs.%20RESULTS%3A%20The%20distribution%20of%20age%2C%20sex%20and%20CD4%20count%20at%20ART%20initiation%20was%20similar%20across%20Youth%20Clinic%20A%20%28N%20%3D%201383%29%2C%20Youth%20Clinic%20B%20%28N%20%3D%201299%29%20and%20general%20clinics%20%28N%20%3D%203056%29.%20Youth%20at%20youth%20clinics%20were%20more%20likely%20than%20those%20at%20general%20clinics%20to%20have%20initiated%20ART%20before%20August%202011%20%28Youth%20Clinic%20A%3A%2016%25%2C%20Youth%20Clinic%20B%3A%2023%25%20and%20general%20clinics%3A%2011%25%29.%20Youth%20clinics%20were%20protective%20against%20attrition%3A%20HR%200.81%20%2895%25%20CI%3A%200.71-0.92%29%20for%20Youth%20Clinic%20A%20and%200.85%20%280.74-0.98%29%20for%20Youth%20Clinic%20B%2C%20compared%20to%20general%20clinics.%20Youth%20Clinic%20A%20club%20patients%20had%20lower%20attrition%20after%20joining%20an%20adherence%20club%20than%20general%20clinic%20patients%20in%20adherence%20clubs%20%28crude%20HR%3A%200.56%2C%2095%25%20CI%3A%200.32-0.96%3B%20adjusted%20HR%3A%200.48%2C%2095%25%20CI%3A%200.28-0.85%29%2C%20while%20Youth%20Clinic%20B%20showed%20no%20effect%20%28crude%20HR%3A%200.83%2C%2095%25%20CI%3A%200.48-1.45%3B%20adjusted%20HR%3A%201.07%2C%2095%25%20CI%3A%200.60-1.90%29.%20CONCLUSIONS%3A%20YLWH%20were%20more%20likely%20to%20be%20retained%20in%20ART%20care%20in%20two%20different%20youth-targeted%20clinics%20compared%20to%20general%20clinics%20in%20the%20same%20area.%20Our%20findings%20suggest%20that%20multiple%20approaches%20to%20making%20clinics%20more%20youth-friendly%20can%20contribute%20to%20improving%20retention%20in%20this%20important%20group.%22%2C%22date%22%3A%22Jan%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25854%22%2C%22ISSN%22%3A%221758-2652%20%28Electronic%29%201758-2652%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22TCMBXKKM%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A16%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22YUUBPBD9%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Romo%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BRomo%2C%20M.%20L.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BPatel%2C%20R.%20C.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEdwards%2C%20J.%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BHumphrey%2C%20J.%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMusick%2C%20B.%20S.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Disparities%20in%20Dolutegravir%20Uptake%20Affecting%20Females%20of%20Reproductive%20Age%20With%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%20After%20Initial%20Concerns%20About%20Teratogenicity%26%23x202F%3B%3A%20An%20Observational%20Study.%20%26lt%3Bi%26gt%3BAnn%20Intern%20Med%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B175%26lt%3B%5C%2Fi%26gt%3B%20%281%29%2C%20S.%2084%26%23x2013%3B94.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3037%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3037%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disparities%20in%20Dolutegravir%20Uptake%20Affecting%20Females%20of%20Reproductive%20Age%20With%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%20After%20Initial%20Concerns%20About%20Teratogenicity%20%3A%20An%20Observational%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Romo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20W.%22%2C%22lastName%22%3A%22Maina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Penner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wyka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20S.%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Panczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20A.%22%2C%22lastName%22%3A%22Kelvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20transition%20to%20dolutegravir-containing%20antiretroviral%20therapy%20%28ART%29%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%20was%20complicated%20by%20an%20initial%20safety%20signal%20in%20May%202018%20suggesting%20that%20exposure%20to%20dolutegravir%20at%20conception%20was%20possibly%20associated%20with%20infant%20neural%20tube%20defects.%20On%20the%20basis%20of%20additional%20evidence%2C%20in%20July%202019%2C%20the%20World%20Health%20Organization%20recommended%20dolutegravir%20for%20all%20adults%20and%20adolescents%20living%20with%20HIV.%20OBJECTIVE%3A%20To%20describe%20dolutegravir%20uptake%20and%20disparities%20by%20sex%20and%20age%20group%20in%20LMICs.%20DESIGN%3A%20Observational%20cohort%20study.%20SETTING%3A%2087%20sites%20that%20began%20using%20dolutegravir%20in%2011%20LMICs%20in%20the%20Asia-Pacific%3B%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%3B%20and%20sub-Saharan%20African%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20PATIENTS%3A%20134%20672%20patients%20aged%2016%20years%20or%20older%20who%20received%20HIV%20care%20from%20January%202017%20through%20March%202020.%20MEASUREMENTS%3A%20Sex%2C%20age%20group%2C%20and%20dolutegravir%20uptake%20%28that%20is%2C%20newly%20initiating%20ART%20with%20dolutegravir%20or%20switching%20to%20dolutegravir%20from%20another%20regimen%29.%20RESULTS%3A%20Differences%20in%20dolutegravir%20uptake%20among%20females%20of%20reproductive%20age%20%2816%20to%2049%20years%29%20emerged%20after%20the%20safety%20signal.%20By%20the%20end%20of%20follow-up%2C%20the%20cumulative%20incidence%20of%20dolutegravir%20uptake%20among%20females%2016%20to%2049%20years%20old%20was%2029.4%25%20%2895%25%20CI%2C%2029.0%25%20to%2029.7%25%29%20compared%20with%2057.7%25%20%28CI%2C%2057.2%25%20to%2058.3%25%29%20among%20males%2016%20to%2049%20years%20old.%20This%20disparity%20was%20greater%20in%20countries%20that%20began%20implementing%20dolutegravir%20before%20the%20safety%20signal%20and%20initially%20had%20highly%20restrictive%20policies%20versus%20countries%20with%20a%20later%20rollout.%20Dolutegravir%20uptake%20was%20similar%20among%20females%20and%20males%20aged%2050%20years%20or%20older.%20LIMITATION%3A%20Follow-up%20was%20limited%20to%206%20to%208%20months%20after%20international%20guidelines%20recommended%20expanding%20access%20to%20dolutegravir.%20CONCLUSION%3A%20Substantial%20disparities%20in%20dolutegravir%20uptake%20affecting%20females%20of%20reproductive%20age%20through%20early%202020%20are%20documented.%20Although%20this%20disparity%20was%20anticipated%20because%20of%20country-level%20restrictions%20on%20access%2C%20the%20results%20highlight%20its%20extent%20and%20initial%20persistence.%20PRIMARY%20FUNDING%20SOURCE%3A%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%22Jan%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-3037%22%2C%22ISSN%22%3A%221539-3704%20%28Electronic%29%200003-4819%20%28Print%29%200003-4819%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A18%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22AMM6W376%22%2C%22library%22%3A%7B%22id%22%3A2775998%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zurcher%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A16%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3B%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BZurcher%2C%20K.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BCox%2C%20S.%20R.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BBallif%2C%20M.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BEnane%2C%20L.%20A.%26lt%3B%5C%2Fspan%26gt%3B%3B%20%26lt%3Bspan%20style%3D%26quot%3Btext-decoration%3Anone%3B%26quot%3B%26gt%3BMarcy%2C%20O.%26lt%3B%5C%2Fspan%26gt%3B%20et%20al.%26lt%3B%5C%2Fspan%26gt%3B%20%282022%29.%20Integrating%20services%20for%20HIV%20and%20multidrug-resistant%20tuberculosis%3A%20A%20global%20cross-sectional%20survey%20among%20ART%20clinics%20in%20low-%20and%20middle-income%20countries.%20%26lt%3Bi%26gt%3BPLOS%20Glob%20Public%20Health%26lt%3B%5C%2Fi%26gt%3B%2C%20%26lt%3Bi%26gt%3B2%26lt%3B%5C%2Fi%26gt%3B%20%283%29%2C%20S.%20e0000180.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000180%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000180%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Integrating%20services%20for%20HIV%20and%20multidrug-resistant%20tuberculosis%3A%20A%20global%20cross-sectional%20survey%20among%20ART%20clinics%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Zurcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20R.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Reubenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Imsanguan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Suryavanshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Tornheim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aids%22%2C%22lastName%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20the%20leading%20cause%20of%20death%20among%20PLHIV%20and%20multidrug-resistant-TB%20%28MDR-TB%29%20is%20associated%20with%20high%20mortality.%20We%20examined%20the%20management%20for%20adult%20PLHIV%20coinfected%20with%20MDR-TB%20at%20ART%20clinics%20in%20lower%20income%20countries.%20Between%202019%20and%202020%2C%20we%20conducted%20a%20cross-sectional%20survey%20at%2029%20ART%20clinics%20in%20high%20TB%20burden%20countries%20within%20the%20global%20IeDEA%20network.%20We%20used%20structured%20questionnaires%20to%20collect%20clinic-level%20data%20on%20the%20TB%20and%20HIV%20services%20and%20the%20availability%20of%20diagnostic%20tools%20and%20treatment%20for%20MDR-TB.%20Of%2029%20ART%20clinics%2C%2025%20%2886%25%29%20were%20in%20urban%20areas%20and%2019%20%2866%25%29%20were%20tertiary%20care%20clinics.%20Integrated%20HIV-TB%20services%20were%20reported%20at%2025%20%2886%25%29%20ART%20clinics%20for%20pan-susceptible%20TB%2C%20and%2014%20%2848%25%29%20clinics%20reported%20full%20MDR-TB%20services%20on-site%2C%20i.e.%20drug%20susceptibility%20testing%20%5BDST%5D%20and%20MDR-TB%20treatment.%20Some%20form%20of%20DST%20was%20available%20on-site%20at%2022%20%2876%25%29%20clinics%2C%20while%20the%20remainder%20referred%20testing%20off-site.%20On-site%20DST%20for%20second-line%20drugs%20was%20available%20at%209%20%2831%25%29%20clinics.%20MDR-TB%20treatment%20was%20delivered%20on-site%20at%2015%20%2852%25%29%20clinics%2C%20with%2010%20individualizing%20treatment%20based%20on%20DST%20results%20and%20five%20using%20standardized%20regimens%20alone.%20Bedaquiline%20was%20routinely%20available%20at%205%20%2817%25%29%20clinics%20and%20delamanid%20at%203%20%2810%25%29%20clinics.%20Although%20most%20ART%20clinics%20reported%20having%20integrated%20HIV%20and%20TB%20services%2C%20few%20had%20fully%20integrated%20MDR-TB%20services.%20There%20is%20a%20continued%20need%20for%20increased%20access%20to%20diagnostic%20and%20treatment%20options%20for%20MDR-TB%20patients%20and%20better%20integration%20of%20MDR-TB%20services%20into%20the%20HIV%20care%20continuum.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pgph.0000180%22%2C%22ISSN%22%3A%222767-3375%20%28Electronic%29%202767-3375%20%28Linking%29%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22GXCKG69T%22%2C%22ZVWK2Q45%22%2C%22D9WC3N3V%22%2C%22TCMBXKKM%22%2C%228IRGNQWZ%22%2C%22F2Y6PLUL%22%2C%22ZBJI578D%22%2C%22YAE5EUBI%22%2C%223FNU2D64%22%5D%2C%22dateModified%22%3A%222023-08-20T14%3A36%3A43Z%22%7D%7D%5D%7D
Nyakato, P.; Christ, B.; Anderegg, N.; Muhairwe, J.; Jefferys, L. et al. (2022). High Unreported Mortality in Children and Youth (<25 Years) Living With HIV Who Were Lost to Care From Antiretroviral Therapy Programs in Southern Africa: Results From a Multicountry Tracing Study. J Acquir Immune Defic Syndr, 91 (5), S. 429–433. http://doi.org/10.1097/QAI.0000000000003090.
McCann, N. C.; Stanic, T.; Penazzato, M.; Flanagan, C. F.; Abrams, E. J. et al. (2022). Prevalence of undiagnosed HIV among children in South Africa, Cote d’Ivoire and Zimbabwe: a model-based analysis to inform paediatric HIV screening programmes. J Int AIDS Soc, 25 (12), S. e26045. http://doi.org/10.1002/jia2.26045.
Chihota, B. V.; Mandiriri, A.; Shamu, T.; Muula, G.; Nyamutowa, H. et al. (2022). Metabolic syndrome among treatment-naive people living with and without HIV in Zambia and Zimbabwe: a cross-sectional analysis. J Int AIDS Soc, 25 (12), S. e26047. http://doi.org/10.1002/jia2.26047.
Brazier, E.; Ajeh, R.; Maruri, F.; Musick, B.; Freeman, A. et al. (2022). Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium. J Int AIDS Soc, 25 (12), S. e26036. http://doi.org/10.1002/jia2.26036.
Iskandar, R.; Taghavi, K.; Low, N.; Bramer, W. M.; Egger, M. et al. (2022). Mathematical Models for Evaluating Effectiveness and Cost-Effectiveness of Cervical Cancer Control Policies in Populations Including Women Living With Human Immunodeficiency Virus: A Scoping Review. Value Health Reg Issues, 32, S. 39–46. http://doi.org/10.1016/j.vhri.2022.07.001.
Tlali, M.; Scheibe, A.; Ruffieux, Y.; Cornell, M.; Wettstein, A. E. et al. (2022). Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study. Int J Drug Policy, 109, S. 103853. http://doi.org/10.1016/j.drugpo.2022.103853.
Kassanjee, Reshma; Davies, Mary-Ann; Ngwenya, Olina; Osei-Yeboah, Richard; Jacobs, Theuns et al. (2022). COVID-19 among adults living with HIV: Correlates of mortality in a general population in a resource-limited setting. MedRxiv: The Preprint Server for Health Sciences, S. 2022.10.17.22281085. http://doi.org/10.1101/2022.10.17.22281085.
Marti, M.; Zurcher, K.; Enane, L. A.; Diero, L.; Marcy, O. et al. (2022). Impact of the COVID-19 pandemic on TB services at ART programmes in low- and middle-income countries: a multi-cohort survey. J Int AIDS Soc, 25 (10), S. e26018. http://doi.org/10.1002/jia2.26018.
Turdo, Y. Q.; Ruffieux, Y.; Boshomane, T. M. G.; Mouton, H.; Taghavi, K. et al. (2022). Cancer treatment and survival among cervical cancer patients living with or without HIV in South Africa. Gynecol Oncol Rep, 43, S. 101069. http://doi.org/10.1016/j.gore.2022.101069.
Shamu, T.; Rohner, E.; Chokunonga, E.; Spoerri, A.; Mandiriri, A. et al. (2022). Cancer incidence among people living with HIV in Zimbabwe: A record linkage study. Cancer Rep (Hoboken), 5 (10), S. e1597. http://doi.org/10.1002/cnr2.1597.
Kalua, T.; Egger, M.; Jahn, A.; Chimpandule, T.; Kolola, R. et al. (2022). HIV suppression was maintained during the COVID-19 pandemic in Malawi: a program-level cohort study. J Clin Epidemiol, 150, S. 116–125. http://doi.org/10.1016/j.jclinepi.2022.06.019.
Kubjane, M.; Osman, M.; Boulle, A. & Johnson, L. F. (2022). The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis. Int J Infect Dis, 122, S. 811–819. http://doi.org/10.1016/j.ijid.2022.07.047.
Wada, P. Y.; Kim, A.; Jayathilake, K.; Duda, S. N.; Abo, Y. et al. (2022). Site-Level Comprehensiveness of Care Is Associated with Individual Clinical Retention Among Adults Living with HIV in International Epidemiology Databases to Evaluate AIDS, a Global HIV Cohort Collaboration, 2000-2016. AIDS Patient Care STDS, 36 (9), S. 343–355. http://doi.org/10.1089/apc.2022.0042.
Edmonds, A.; Brazier, E.; Musick, B. S.; Yotebieng, M.; Humphrey, J. et al. (2022). Clinical and programmatic outcomes of HIV-exposed infants enrolled in care at geographically diverse clinics, 1997-2021: A cohort study. PLoS Med, 19 (9), S. e1004089. http://doi.org/10.1371/journal.pmed.1004089.
Asangbeh-Kerman, S. L.; Davidovic, M.; Taghavi, K.; Kachingwe, J.; Rammipi, K. M. et al. (2022). Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies. BMC Public Health, 22 (1), S. 1530. http://doi.org/10.1186/s12889-022-13827-0.
Hauser, A.; Goldstein, F.; Reichmuth, M. L.; Kouyos, R. D.; Wandeler, G. et al. (2022). Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. J Clin Epidemiol, 148, S. 135–145. http://doi.org/10.1016/j.jclinepi.2022.02.005.
Christ, B.; van Dijk, J. H.; Nyandoro, T. Y.; Reichmuth, M. L.; Kunzekwenyika, C. et al. (2022). Availability and experiences of differentiated antiretroviral therapy delivery at HIV care facilities in rural Zimbabwe: a mixed-method study. J Int AIDS Soc, 25 (8), S. e25944. http://doi.org/10.1002/jia2.25944.
Davies, Mary-Ann; Morden, Erna; Rosseau, Petro; Arendse, Juanita; Bam, Jamy-Lee et al. (2022). Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. MedRxiv: The Preprint Server for Health Sciences, S. 2022.06.28.22276983. http://doi.org/10.1101/2022.06.28.22276983.
Lewis, J. T.; Stephens, J.; Musick, B.; Brown, S.; Malateste, K. et al. (2022). The IeDEA harmonist data toolkit: A data quality and data sharing solution for a global HIV research consortium. J Biomed Inform, 131, S. 104110. http://doi.org/10.1016/j.jbi.2022.104110.
Chihota, B. V.; Riebensahm, C.; Muula, G.; Sinkala, E.; Chilengi, R. et al. (2022). Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. BMJ Open Gastroenterol, 9 (1), S. e000945. http://doi.org/10.1136/bmjgast-2022-000945.
Romo, M. L.; Brazier, E.; Mahambou-Nsonde, D.; De Waal, R.; Sekaggya-Wiltshire, C. et al. (2022). Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa. J Int AIDS Soc, 25 (7), S. e25961. http://doi.org/10.1002/jia2.25961.
Kalk, E.; Heekes, A.; Slogrove, A. L.; Phelanyane, F.; Davies, M. A. et al. (2022). Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER). BMJ Open, 12 (6), S. e060205. http://doi.org/10.1136/bmjopen-2021-060205.
Wettstein, A.; Tlali, M.; Joska, J. A.; Cornell, M.; Skrivankova, V. W. et al. (2022). The effect of the COVID-19 lockdown on mental health care use in South Africa: an interrupted time-series analysis. Epidemiol Psychiatr Sci, 31, S. e43. http://doi.org/10.1017/S2045796022000270.
van der Hoven, J.; Allen, E.; Cois, A.; de Waal, R.; Maartens, G. et al. (2022). Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment. BMC Pregnancy Childbirth, 22 (1), S. 466. http://doi.org/10.1186/s12884-022-04765-1.
Davies, Mary-Ann; Kassanjee, Reshma; Rousseau, Petro; Morden, Erna; Johnson, Leigh et al. (2022). Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Tropical Medicine & International Health: TM & IH, 27 (6), S. 564–573. http://doi.org/10.1111/tmi.13752.
Zurcher, K.; Riou, J.; Morrow, C.; Ballif, M.; Koch, A. et al. (2022). Estimating Tuberculosis Transmission Risks in a Primary Care Clinic in South Africa: Modeling of Environmental and Clinical Data. J Infect Dis, 225 (9), S. 1642–1652. http://doi.org/10.1093/infdis/jiab534.
Hussey, H.; Davies, M. A.; Heekes, A.; Williamson, C.; Valley-Omar, Z. et al. (2022). Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis. Int J Infect Dis, 118, S. 150–154. http://doi.org/10.1016/j.ijid.2022.02.051.
Muchengeti, M.; Bartels, L.; Olago, V.; Dhokotera, T.; Chen, W. C. et al. (2022). Cohort profile: the South African HIV Cancer Match (SAM) Study, a national population-based cohort. BMJ Open, 12 (4), S. e053460. http://doi.org/10.1136/bmjopen-2021-053460.
Davies, C.; Johnson, L.; Sawry, S.; Chimbetete, C.; Eley, B. et al. (2022). Effect of antiretroviral therapy care interruptions on mortality in children living with HIV. AIDS, 36 (5), S. 729–737. http://doi.org/10.1097/QAD.0000000000003194.
Staub, K.; Panczak, R.; Matthes, K. L.; Floris, J.; Berlin, C. et al. (2022). Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain. Ann Intern Med, 175 (4), S. 523–532. http://doi.org/10.7326/M21-3824.
Antimycobacterial Susceptibility Testing, Group (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J, 59 (4), S. 2200166. http://doi.org/10.1183/13993003.00166-2022.
Justice, A. C.; Goetz, M. B.; Stewart, C. N.; Hogan, B. C.; Humes, E. et al. (2022). Delayed presentation of HIV among older individuals: a growing problem. Lancet HIV, 9 (4), S. e269–e280. http://doi.org/10.1016/S2352-3018(22)00003-0.
Riebensahm, C.; Chitundu, H.; Muula, G.; Chihota, B.; Sinkala, E. et al. (2022). Screening for hepatocellular carcinoma among adults with HIV/HBV co-infection in Zambia: a pilot study. Int J Infect Dis, 116, S. 391–396. http://doi.org/10.1016/j.ijid.2021.12.338.
Collaborative Initiative for Paediatric, H. I. V. Education; Research Global Cohort, Collaboration; Jesson, J.; Crichton, S.; Quartagno, M. et al. (2022). Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. J Int AIDS Soc, 25 (3), S. e25871. http://doi.org/10.1002/jia2.25871.
Taghavi, K.; Mandiriri, A.; Shamu, T.; Rohner, E.; Butikofer, L. et al. (2022). Cervical Cancer Screening Cascade for women living with HIV: a cohort study from Zimbabwe. PLOS Glob Public Health, 2 (2), S. e0000156. http://doi.org/10.1371/journal.pgph.0000156.
Ballif, Marie; Christ, Benedikt; Anderegg, Nanina; Chammartin, Frédérique; Muhairwe, Josephine et al. (2022). Tracing People Living With Human Immunodeficiency Virus Who Are Lost to Follow-up at Antiretroviral Therapy Programs in Southern Africa: A Sampling-Based Cohort Study in 6 Countries. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 74 (2), S. 171–179. http://doi.org/10.1093/cid/ciab428.
Dhokotera, T.; Asangbeh, S.; Bohlius, J.; Singh, E.; Egger, M. et al. (2022). Cervical cancer in women living in South Africa: a record linkage study of the National Health Laboratory Service and the National Cancer Registry. Ecancermedicalscience, 16, S. 1348. http://doi.org/10.3332/ecancer.2022.1348.
Davies, M. A.; Kassanjee, R.; Rosseau, P.; Morden, E.; Johnson, L. et al. (2022). Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. MedRxiv, S. 2022.01.12.22269148. http://doi.org/10.1101/2022.01.12.22269148.
Nyemba, D. C.; Kalk, E.; Vinikoor, M. J.; Madlala, H. P.; Mubiana-Mbewe, M. et al. (2022). Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia. BMC Public Health, 22 (1), S. 55. http://doi.org/10.1186/s12889-021-12476-z.
Nyakato, P.; Schomaker, M.; Fatti, G.; Tanser, F.; Euvrard, J. et al. (2022). Virologic non-suppression and early loss to follow up among pregnant and non-pregnant adolescents aged 15-19 years initiating antiretroviral therapy in South Africa: a retrospective cohort study. J Int AIDS Soc, 25 (1), S. e25870. http://doi.org/10.1002/jia2.25870.
Cassidy, T.; Cornell, M.; Runeyi, P.; Dutyulwa, T.; Kilani, C. et al. (2022). Attrition from HIV care among youth initiating ART in youth-only clinics compared with general primary healthcare clinics in Khayelitsha, South Africa: a matched propensity score analysis. J Int AIDS Soc, 25 (1), S. e25854. http://doi.org/10.1002/jia2.25854.
Romo, M. L.; Patel, R. C.; Edwards, J. K.; Humphrey, J. M.; Musick, B. S. et al. (2022). Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study. Ann Intern Med, 175 (1), S. 84–94. http://doi.org/10.7326/M21-3037.
Zurcher, K.; Cox, S. R.; Ballif, M.; Enane, L. A.; Marcy, O. et al. (2022). Integrating services for HIV and multidrug-resistant tuberculosis: A global cross-sectional survey among ART clinics in low- and middle-income countries. PLOS Glob Public Health, 2 (3), S. e0000180. http://doi.org/10.1371/journal.pgph.0000180.
Contact Us